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ABSTRACT
Marketed as a safer alternative to tobacco products, the popularity of e-cigarette use is on
the rise. However, little is known about the potential health risks associated with their use.
Many e-cigarette filling solutions are known to contain significant levels of tobacco
alkaloids, including nicotine, anabasine, myosmine and cotinine. Using a panel of lung cell
cultures distinguished by differences in sex and disease status, this study addresses the in
vitro effects of common tobacco alkaloids found in e-cigarettes on cell proliferation and
gene expression. We hypothesize that alkaloid exposure of lung cells is associated with
abnormal proliferation and gene expression, and predict that cellular response to the
alkaloids will present in a sex-specific manner. Alkaloid exposure on each lung cell line
was evaluated at 1 µg/mL, 10 µg/mL, and 100 µg/mL concentrations throughout a 10-day
time course. Cellular proliferation was measured daily using the CellTiter-Glo®
Luminescent Viability Assay, and RNA isolated after 48 and 96-hour time points for gene
expression analysis of 10 cancer biomarkers by qRT-PCR. Findings indicate anabasine and
myosmine display a significant (p<0.05) inhibitory effect on cellular proliferation and gene
expression, whereas the effect of cotinine and nicotine was minimal. Each cell line had an
inherent, characteristic pattern of cellular proliferation in response to alkaloid exposure.
Notably, the cancer cell line demonstrated more variability among replicates, which we
attribute to the non-clonal nature of this cell line, and the female cell line displayed
increased susceptibility to toxicity by the higher alkaloid concentrations. Significant
differences in gene expression (p<0.05) were noted for AHR, CEACAM6, CYP1A1,
MDM2, TP53, ALDH3A1 and GPX2. Correlation of abnormal patterns of cell proliferation
and differential gene expression with risk for disease are discussed.
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INTRODUCTION
Background
Marketed as a smarter alternative to smoking tobacco cigarettes, by 2014, the
popularity of electronic cigarettes (e-cigarettes) had resulted in a 2.5 billion dollar business
within the United States (Surgeon General, 2016). Though they continue to increase in
popularity today, little research has been provided to validate a common assumption that
e-cigarettes are a safer alternative to traditional cigarettes. This notion, regarding the
perceived safety of e-cigarettes, has been examined in multiple studies including a report
published in 2015 in the Journal of Behavioral Medicine. Findings from this study
indicated that more people than not, believed the use of e-cigarettes resulted in fewer health
effects in comparison to traditional cigarettes (Pepper, Emery, Ribisl, Rini, & Brewer,
2015). It was also found that among participants of this study, women felt more this way
than men (Pepper et al., 2015).
Worse yet, two different reports found that the trend of smoking e-cigarettes
extends to the youth as well, not just adults (Arrazola et al., 2015; Surgeon General, 2016).
More than likely appealed to with flavorings such as bubble-gum and candy apple, in the
United States alone it is estimated that in 2014 there were 2.4 million e-cigarette users that
were youth and young adults (Arrazola et al., 2015). Accordingly, in 2016 the U.S. Surgeon
General responded to this rise in e-cigarette use among youth and young adults with a
report detailing the increasing evidence that suggests that adolescents and young adults
should be warned and advised against the use of e-cigarettes due to the risk of exposure to
several chemicals that could have adverse health effects on youth and young adults
(Surgeon General, 2016). These chemicals included nicotine, which has been found to
6

cause addiction and harm to the developing brain as well as acute toxicity and/or death if
larger quantities of e-cigarette filling solution containing nicotine are ingested (Surgeon
General, 2016).
With so much confusion among consumers as to the impact and potential harm that
e-cigarette use can have on the human body, a thorough scientific analysis of every possible
health related concern should be investigated. Only with thorough scientific investigation
of e-cigarette use can consumers have the tools to base a more meaningful decision that
may greatly impact their present and future health. The purpose of this study is to contribute
to the scientific investigation of e-cigarette use by studying tobacco alkaloids that have
been found to be within e-cigarette filling solutions and their effect on cell proliferation
and gene expression.

Electronic Cigarette Design
To better understand the effects of e-cigarette use, it is important to understand the
workings of the delivery system, as well as the compounds within the filling solutions that
are delivered through the e-cigarette device. Historical background into the e-cigarette and
its delivery system, includes the introduction of the device to the United States in 2007,
although the modern version of the electronic cigarette that is most recognized today was
first developed and patented by Hon Lik, a Chinese Pharmacist, in 2003 (Grana, Benowitz,
& Glantz, 2013). Simultaneously called an electronic nicotine delivery system (ENDS),
the device consists of a battery, vaporizer, cartridge containing filling solution with or
without nicotine, LED light at the end, heating coil, atomizer, and a mouthpiece (Figure 1).
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Figure 1: Diagram of Structural Components of Electronic Cigarette
The yellow in the drawing indicates the location of the LED light at the end of the cigarette;
the white area of the drawing is the region that holds the battery; the silver portion of the
drawing represents the area that houses the voltage control; the black portion of the drawing
represents the area where the heating coil, atomizer, vaporizing chamber, and filling solution
are housed.

By drawing in air through the mouthpiece, the battery of the electronic device is
activated by varying methods, and which in turn initiates the atomizer, that ultimately
produces aerosol from the filling solution composed of propylene glycol and/or glycerol,
nicotine, additives and/or added flavorings (Cheng, 2014; Grana et al., 2013; Surgeon
General, 2016). This aerosol, usually incorrectly perceived as vapor, exits through the
mouthpiece and into the mouth and lungs of the user (Cheng, 2014). Since the introduction
of e-cigarettes into the United States, many varying designs, makes, and models have
arrived on the market, yet all still similarly produce an aerosol usually composed of
nicotine, flavoring, and additives into the user’s mouth and lungs (Surgeon General, 2016).

Tobacco Alkaloids Commonly Found in E-cigarette Filling Solutions
There are a variety of different nicotine and non-nicotine filling solutions, and at
this time, the manufacturers do not usually disclose the complete chemistry involved in ecigarette filling solutions. As more studies show that toxic and carcinogenic compounds
are present within these filler solutions, further research is warranted into how these
unspecified compounds found in e-cigarettes are affecting the human body (Cheng, 2014).
Besides chromatographic analysis detecting fluctuating levels of nicotine in products
advertised as nicotine-free, filler solutions have also been shown to contain the chemical
compounds cotinine, anabasine, and myosmine (Trehy et al., 2011). Research has shown
8

these common tobacco alkaloid compounds to have synergistic effects on nicotine in
regards to addiction (Clemens, Caillé, Stinus, & Cador, 2009), however, data on the effects
within areas of the human body other than addiction is limited, and warrants more research.

Nicotine

Existing as an oily liquid that is colorless to pale yellow and quickly turns brown
when exposed to light or air, nicotine is a compound that can be isolated from the dried
leaves of the Nicotiana tabacum and N. rustica tobacco plants (O'Neil, 2006). Within these
plants it can make up between 2-8% of the plant material and combines with both malic
and citric acid (O'Neil, 2006). In tobacco plants, nicotine serves as a natural defense
system, effectively as an insecticide. It is known to be the most abundant alkaloid within
tobacco (O'Neil, 2006). In regards to humans, the alkaloid tends to be the most addictive
of the tobacco alkaloids when used recreationally (General, 1988). The addictive nature of
nicotine lies in its ability to readily diffuse into brain tissue upon ingestion and entering
into the bloodstream (Benowitz, 2008). Once nicotine has diffused into the brain, the
compound binds to nicotinic cholinergic receptors (nAChRs), described as ligand-gated
ion channels, ultimately triggering the release of neurotransmitters such as dopamine,
norepinephrine, acetylcholine, serotonin, endorphins, and others that help to facilitate its
physically addicting nature (Benowitz, 2008).

9

Figure 2: Chemical Structure of Nicotine

In regards to smoking tobacco cigarettes, nicotine is thought to be absorbed by the
user at around 0.5-2 mg per cigarette on average, depending on how frequently the user
inhales (puffs) on a cigarette (Benowitz, 1983; Benowitz & Jacob, 1984), though tobacco
cigarettes themselves are comprised of anywhere from 10-15 mg of nicotine per cigarette
on average (Kozlowski et al., 1998; Malson, Sims, Murty, & Pickworth, 2001). Within ecigarette filling solution there is much more variance concerning the concentration of
nicotine (Trehy et al., 2011). The concentration of nicotine within e-cigarette filling
solution cartridges has been seen to be as low as 0 mg/cartridge and as high as 21.82
mg/cartridge, and varying levels of nicotine have even been detected among filling
solutions that has been advertised as nicotine-free (Trehy et al., 2011). The amount of
nicotine absorbed by the user has been determined to be concentration dependent, relying
greatly on the amount of inhalations (puffs) the user takes from the device and in what time
frame, since greater amounts of nicotine are seen to be absorbed with greater amounts of
heat created within the e-cigarette device and these greater amounts of heat are ultimately
caused by a greater amount of puffs by the user, in shorter amounts of time (Grana et al.,
2013; Trehy et al., 2011).
10

Once inhaled, nicotine can be absorbed through not only the mucosal lining of the
mouth, but also substantially in the alveoli of the lungs and the bronchial tree (Benowitz,
1983). A contributing factor to varying nicotine absorption in the mucosal lining is the pH
of the smoke inhaled (Benowitz, 1983). Nicotine is a weak base with a pH of 8.0, and in
its ionized state it does not readily cross membranes, such as when nicotine is within fluecured tobacco smoke, which has an acidic pH (Benowitz, Hukkanen, & Jacob, 2009; Gori,
Benowitz, & Lynch, 1986). Cigars, however, tend to have a more alkaline smoke that is
inhaled by a user than that of the smoke produced by cigarettes, and because of this, more
nicotine is absorbed in the user’s mucosal lining by cigars (A. Armitage & Turner, 1970).
Nicotine is also found to be readily absorbed through the skin, most notably causing
an illness called, green tobacco sickness (GTS), which has been studied among individuals
who handle tobacco leaves, such as tobacco workers whom are involved in the cutting,
harvesting, or loading of the plants (McBride, Altman, Klein, & White, 1998). Once
nicotine has been absorbed by the body, it spreads to all the bodily tissues fairly quickly,
becoming metabolized primarily in the liver, and a small amount excreted by the kidneys
(Benowitz, 1983). Nicotine also has an affinity for brain tissue, seen to be greater in regular
tobacco smokers than non-smokers, and is known to cause both a stimulatory effect on
neuronal nicotinic receptors as well as the possibility of receptor desensitization (Balfour,
1994; Benwell, Balfour, & Anderson, 1988; Breese et al., 1997; Hukkanen, Jacob, &
Benowitz, 2005).
Perhaps most alarming to the health of the user of nicotine containing products, is
that nicotine is also a tertiary amine, and tertiary amines are known to form stable
nitrosamines with nitrosating agents, and that nicotine in particular has been implicated in
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the formation of tobacco-specific nitrosamines (TSNAs) within the body (Hecht &
Hoffmann, 1988; Knezevich, Muzic, Hatsukami, Hecht, & Stepanov, 2013) (Figure 3).
TSNAs are regarded as a highly carcinogenic group related to tobacco and tobacco smoke
(Hecht & Hoffmann, 1988; Knezevich et al., 2013). The nicotine induced TSNAs are
specifically, NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and NNN (N’nitrosonornicotine), both of which can contribute to tumors. NNK, in particular,
demonstrates an organ localization specificity for the lung (Hecht & Hoffmann, 1988).
Once activated, the nitrosamines, NNK and NNN, also have been seen to lead to a reactive
intermediate that binds to and chemically modifies DNA and proteins (Wilp,
Zwickenpflug, & Richter, 2002). It has been suggested that these modifications are
contributing factors to carcinogenesis (Hecht & Hoffmann, 1988).

Figure 3: Chemical Structure of a Nitrosamine

In regards to how long nicotine remains in the body, nicotine levels detected in the
blood after smoking one tobacco cigarette tend to have a half-life of only 5-10 minutes,
with levels varying per user due to differences among individuals in metabolism rate,
smoking style, and specific nicotine product (Benowitz, 1983; Benowitz, Jacob, Jones, &
Rosenberg, 1982). However, a nicotine half-life of around two hours can be detected in the
12

blood of individuals who are absorbing nicotine over longer periods of time or after the
administration of multiple doses (Benowitz, 1983). Studies carried out to determine the
arterial concentration levels of nicotine in smokers has found levels ranging in individuals
from 20-60 ng/mL, and as high as 100 ng/mL (A. K. Armitage et al., 1975; Gori & Lynch,
1985; Henningfield, Stapleton, Benowitz, Grayson, & London, 1993; Hukkanen et al.,
2005). Theses previous studies indicating different concentration levels at different time
points among tobacco smokers, coupled with the risk of carcinogenic TSNAs being derived
from nicotine, warrants further research in investigating varying ranges of nicotine
exposure due to e-cigarette filling solution and possible adverse health side-effects among
its users.

Cotinine

Described physically as a viscous oil, cotinine is a tobacco alkaloid that is a result
of nicotine metabolism (Benowitz, 1983; O'Neil, 2006). It is thought that as much as 86%
of nicotine is metabolized into cotinine, and that detection of cotinine can be utilized as an
indicator of exposure to cigarette smoke (Benowitz, 1983; Bernert et al., 1997; Hukkanen
et al., 2005). Cotinine levels are seen at their highest within the liver, and cotinine itself
metabolizes even further into trans-3’-hydroxycotinine (Benowitz & Hatsukami, 1998).
Cotinine has shown less variability in the time in which it is metabolized in individuals
than has been seen with nicotine, and it has also been shown to have a much longer half13

life, varying from 10.9 to 37.0 hours in one study (Benowitz, 1983). This longer half-life
also makes cotinine a more stable indicator in determining blood concentrations levels
throughout the day of a smoker than nicotine does, and the concentration levels of cotinine
in the blood of smokers tends to be much higher than nicotine (Benowitz, 1983; Hukkanen
et al., 2005).

Figure 4: Chemical Structure of Cotinine

Cotinine blood concentration levels in smokers average about 250 to 300 ng/mL,
and can get up to 900 ng/mL, which is much higher than the concentration levels of nicotine
seen in smokers (N. L. Benowitz et al., 1983). Even with these higher concentration levels
seen within the blood of individuals, research carried out to discover any detrimental effect
of the alkaloid has found that cotinine does not seem to cause cardiovascular effects on
individuals, nor does it seem to have any cognitive effects such as an effect on performance
or noticeable withdrawal symptoms (Benowitz, Kuyt, Jacob, Jones, & Osman, 1983;
Hatsukami, Grillo, Pentel, Oncken, & Bliss, 1997; Zevin, Jacob Iii, Geppetti, & Benowitz,
2000). By studying this alkaloid at different concentrations levels in regards to cell
exposure; evidence promoting or contradicting previous research to its relatively mild
effects will prove to be beneficial in evaluating the effect this alkaloid has within e-cigarette
filling solution, on the e-cigarette user.
14

Myosmine

Myosmine is a naturally occurring minor alkaloid within tobacco plants, and though
it is structurally like nicotine, it is not produced through the metabolism of nicotine such
as with cotinine (Fejér-Kossey, 1972; Simeonova, Vitcheva, Gorneva, & Mitcheva, 2012).
However, myosmine is similar to nicotine in that, along with studies showing that nicotine,
under conditions of nitrosation, gives rise to NNK (4-(methylnitrosamino)-1-(3-pyridyl)1-butanone) and NNN ( N’-nitrosonornicotine) nitrosamines, myosmine has also been
shown upon nitrosation to give rise to the NNN nitrosamine, a known esophageal
carcinogen, as well as another nitrosamine, HPB (4-hydroxy-1-(3-pyridyl)-1-butanone)
(Hecht & Hoffmann, 1988; Wilp et al., 2002). HPB is different from NNN, in that it is the
product of the formation of DNA adducts (sections of DNA covalently bound to a
carcinogen(s)), and can even be used as an indicator of exposure to TSNAs from tobacco
(Wilp et al., 2002).
In some studies, myosmine was seen to be readily nitrosated in the stomach and
lower esophagus under the conditions of GERD/GORD (gastro-esophageal reflux disease
(Vogt, Fuchs, & Richter, 2006; Wilp et al., 2002), posing another possible risk factor for
smokers who also have been diagnosed with GERD/GORD and the possibility of
carcinogenic nitrosamines forming more readily. Along with its ability to readily undergo
nitrosation, myosmine has also been shown to have genotoxic effects on human
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lymphocytes and nasal mucosal cells, and mutagenic effects in human lymphocytes
concerning the MGMT gene when using an HPRT gene mutation assay (Havla, Hill, AbdelRahman, & Richter, 2009; Kleinsasser, Wallner, Harreus, Zwickenpflug, & Richter, 2003).

Figure 5: Chemical Structure of Myosmine

Aside from the concern of this study, myosmine also naturally occurs among other
organisms besides the tobacco plant, and research has found that human exposure can occur
with ingestion of not only tobacco products, but also foods such as peanuts, hazelnuts, rice,
milk, carrots, and many other items (Tyroller, Zwickenpflug, & Richter, 2002;
Zwickenpflug, Meger, & Richter, 1998). As a result, foods such as peanuts and hazelnuts
have also been found to be a possible risk to developing human cancer due to the nitrosation
of the myosmine found within them (Wilp et al., 2002).
Regarding detectable concentration levels of the alkaloid within tobacco cigarettes,
in a plain, unblended tobacco cigarette, myosmine concentration levels have been analyzed
within studies to be between 13-33µg/cigarette in mainstream smoke and 73-224µg
/cigarette in side stream smoke (Sakuma, Kusama, Yamaguchi, Matsuki, & Sugawara,
1984). Myosmine has also been found to be in detectable levels within toenails, saliva, and
plasma (Schütte-Borkovec, Heppel, Heling, & Richter, 2009), but in a study involving IV
16

administration of myosmine to Long-Evans rats, myosmine detection in plasma found it to
have a short half-life of around an hour (Glas et al., 2007; Schutte-Borkovec, Heppel,
Heling, & Richter, 2009). The same study involving the IV administration of myosmine in
Long-Evans rats, also found seemingly high levels of myosmine within the esophagus and
accessory genital gland (Glas et al., 2007). Due to this detection of myosmine in various
tissue throughout the body, its indication of nitrosation into carcinogenic nitrosamines, and
its genotoxic and mutagenic effects on human lymphocytes, more research is warranted
into how this alkaloid can affect lung tissue cells of a user when concentrated within ecigarette filling solution.

Anabasine

Anabasine is another common tobacco alkaloid that, like myosmine, is not the
result of the metabolism of nicotine, but yet is found within the stems and leaves of the
tobacco plant itself (Saitoh, Noma, & Kawashima, 1985). Commonly described as a
piperidine botanical insecticide that exists as a colorless liquid and becomes dark upon air
exposure, anabasine makes up ~0.3% of all of the alkaloids found within the tobacco plant
and although it is considered to be a minor tobacco alkaloid, it can still be used to determine
whether or not someone has had exposure to tobacco or tobacco products (Armstrong,
Wang, Lee, & Liu, 1999; Saitoh et al., 1985). Interestingly, like nicotine, anabasine is also
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considered a nicotinic acetylcholine receptor agonist, and though it has reportedly less
naturally addictive qualities than nicotine, it has been studied as a potentially useful therapy
in relieving nicotine addiction (Nasirov, Ryabchenko, Khalikova, Khazbievich, &
Kashkova, 1978). Anabasine, due to being a secondary amine, also has the capability of
reacting with nitrosating agents to form a more stable, possibly carcinogenic nitrosamine,
similar to nicotine (Hecht & Hoffmann, 1988).

Figure 6: Chemical Structure of Anabasine

In regards to safety hazards when dealing with the compound, anabasine is easily
absorbed through the skin and mucous membranes, and is potentially fatal for humans at a
dose speculated to be less than 5mg/kg (Benowitz, 1983; Neal L. Benowitz et al., 1983;
Gosselin, Smith, & Hodge, 1984; McBride et al., 1998; National Center for Biotechnology
Information). Metabolism of the compound, when based on its half-life determined by rate
of urinary excretion, has been determined to be around 16 hours (Jacob et al., 2002). Due
to evidence of this long half-life in comparison to nicotine metabolism, as well as its
potential to become carcinogenic through interaction with nitrosating agents, makes
investigation of anabasine within e-cigarette filling solution an interesting inquiry within
this study.
18

Candidate Genes Associated with Tobacco-Induced Disease Pathology
The potential cellular and health effects of tobacco use in individuals has been
investigated by researchers throughout the years by varying methods, including, but not
limited to, investigation of differential gene expression among genes with evidence as
being potential cancer and disease biomarkers (U.S. Department of Health and Human
Services, 2010). Genes such as ALDH3A1, which is associated with higher levels of
expression when in the beginning stages of malignant transformation associated with lung
cancer (Patel et al., 2008), CYP1A1, which is associated with xenobiotic (drug)
metabolism (Androutsopoulos, Tsatsakis, & Spandidos, 2009), GPX2, which is associated
with changes seen in oxidative stress-induced apoptosis (Yan & Chen, 2006), and SLIT1,
a tumor suppressor gene (Dickinson et al., 2004), are just a few of the genes that have been
utilized in previous studies throughout the years, as biomarkers, to investigate the potential
health hazards of tobacco use.
The investigation of differential gene expression among known cancer and disease
biomarkers concerning tobacco use also holds potential as a promising method to be
utilized in studies investigating potential cellular and health effects related to tobacco
alkaloids found within e-cigarette filling solution. Within this study, a panel of ten
candidate genes linked to modified gene expression patterns associated with tobacco smoke
exposure, as well as two reference genes, are utilized for gene expression analysis under
varying experimental conditions to investigate any potential hazards that these tobacco
alkaloids may pose to human health (Table 1).
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Table 1: Candidate Genes for Evaluation of Tobacco Alkaloid Induced Carcinogenesis
Gene Description
Candidate Gene SYMBOL
AHR
Oncogene
CEACAM6
Oncogene
PIR**
Oncogene
CYP1A1*
Oncogene
MDM2
Proto-Oncogene
SLIT1**
Tumor Suppressor
TP53*
Tumor Suppressor
CX3CL1**
Immune Response
ALDH3A1
Antioxidant, Cancer-related Enzyme
GPX2
Antioxidant, Cancer-related Enzyme
*Possible differences in gene expression between sexes.
** Unable to investigate expression, at this time, due to unsatisfactory binding of designed primers
and/or low expression levels

TP53
The gene TP53 is a known tumor suppressor gene in humans that is located on the
human chromosome 17p13.1 (National Center for Biotechnology Information) , and in
2013, there were at least 12 known isoforms of its protein, p53, often referred to as the
“guardian of the genome,” due to its ability to protect the cell during times of stress (Sigal
& Rotter, 2000; Surget, Khoury, & Bourdon, 2014). The TP53 gene has many other
homologous forms in other organisms as well, and once the p53 protein is activated, it can
be used to induce various cancer halting mechanisms (Hartl, 2012; Hollstein, Sidransky,
Vogelstein, & Harris, 1991; Surget et al., 2014). Certain types of cellular stress can trigger
the p53 protein to be activated by posttranslational modifications, such as acetylation and
phosphorylation, and these stressors can include a lack of oxygen within the cell, sensed
DNA damage, or a shortage in nucleoside triphosphates (Hartl, 2012). Once the protein has
been activated, it carries out the transcriptional activation and repression of other genes, in
order to achieve effects within the cell such as: apoptosis (also known as the death of cells),
cell cycle arrest, DNA repair, inhibition of angiogenesis and metastasis, as well as other
functions known to be associated with tumor suppression (Hartl, 2012; Ko & Prives, 1996).
20

Believed to be inactivated in nearly 50% of all human cancers (Levine, Momand,
& Finlay, 1991; Surget et al., 2014), TP53 plays an important role in tumorigenesis of lung
epithelial tissue, and mutations of the gene have become some of the most studied
concerning gene mutations involved with lung cancer (Toyooka, Tsuda, & Gazdar, 2003).
While there can be germline mutations within TP53 which can directly cause Li-Fraumeni
syndrome, and germline mutations can pre-dispose one to early cancer onset, it is the
somatic mutations that have been studied extensively among lung cancer research,
especially when lung cancer has been potentially caused by tobacco smoke, a well-known
mutagen (Olivier, Hollstein, & Hainaut, 2010; Toyooka et al., 2003).
In correlation with this study, we hypothesize that TP53 expression is beneficial in
determining if tobacco alkaloids in e-cigarette filling solution can induce a mutated state
within the TP53 gene that can lead to lung cancer. Furthermore, we propose to examine
whether gender has an effect on differential genetic expression of the TP53 gene. This
question has been specifically raised due to a previous study, where it was seen that women
may be more susceptible to lung cancer in the setting of TP53 mutations, due to the finding
of more G:C and T:A transversions within the TP53 gene in female cigarette smokers than
in female non-smokers (Toyooka et al., 2003).

MDM2
An important gene involved in the regulation of the protein produced in humans by
TP53 is the MDM2 gene, which is a known proto-oncogene and is also involved in protein
coding (National Center for Biotechnology Information). The MDM2 gene produces a
nuclear-localized E3 ubiquitin ligase, which mediates the ubiquitination of p53 from TP53,
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which leads to the p53 protein’s subsequent degradation by the proteasome (Harris &
Levine, 2005; National Center for Biotecnology Information). The p53/MDM2 interaction
though is one of an auto-regulatory feedback loop, meaning that p53 induces the expression
of MDM2 as a positive regulator, and then the protein of MDM2 in turn becomes a negative
regulator of p53, limiting its abundance within the cell when under normal cellular
conditions (Harris & Levine, 2005; Hernandez-Monge, Rousset-Roman, Medina-Medina,
& Olivares-Illana, 2016; Shmueli & Oren, 2007). The protein MDM2 is also the binding
substrate for ATM kinase, and in times of genotoxic stress within the cell, ATM
phosphorylates MDM2, exposing a site on the protein that promotes translation of TP53
mRNA (Candeias et al., 2008; Gajjar et al., 2012; Hernandez-Monge et al., 2016).
An overexpression of MDM2 has been seen in many different cancers,
speculatively from its repressive abilities over p53 (Chauhan, Ramakrishnan, Kollareddy,
& Martinez, 2016; National Center for Biotecnology Information). It has also been found,
however, that in addition to factors facilitating overexpression and amplification of the
MDM2 gene directly involving degradation of p53, there is also evidence that
overexpression of MDM2 has a carcinogenic effect on the cell that is completely
independent from any activity involving p53 (Jones, Hancock, Vogel, Donehower, &
Bradley, 1998). Furthermore, in a study published in 2006, it was seen that genetic
polymorphisms that arise within the promoter region of MDM2 have a great impact on the
development of lung cancer within an individual, and that tobacco smoking was also seen
to have an interactive effect with regulation of gene expression of the MDM2 promoter
(Zhang et al., 2006). One particular polymorphism, MDM2-GG, was significantly
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overrepresented in patients with lung cancer (26%) when compared to the control
population (20%) (Zhang et al., 2006).

SLIT1
The human SLIT1 gene is one of a family of three known genes that contribute to
SLIT proteins within humans (Dallol et al., 2002). Within this family, SLIT1 is primarily
considered to be expressed in neuronal tissue, with SLIT2 and SLIT3 being expressed in
greater amounts in various tissues throughout the body in comparison (Dallol et al., 2002).
Though SLIT1 expression levels within human tissues other than neuronal has been thought
to be low (Dickinson et al., 2004), studies have shown it to play a role in prostate cancer,
where expression levels have been shown to be elevated (Latil et al., 2003), as well studies
regarding differential gene expression within lung tissue (Huang, Zheng, VanBuren, &
Zhao, 2010; Spira et al., 2004). In regards to lung cancer found within both tobacco
smokers and non-smokers, SLIT1 has been shown to be downregulated among smokers
with lung cancer (Huang et al., 2010; Spira et al., 2004). This downregulating effect seen
within lung cancer suggests SLIT1 to be a putative tumor suppressor within lung tissue,
and possibly a good biomarker for disease within lung tissue exposed to tobacco alkaloids
(Huang et al., 2010; Spira et al., 2004).

CX3CL1
In studying any diseased state that could occur within the body due to exposure of
e-cigarettes and their filling solution, it would be beneficial to not only study the expression
of genes linked to cancer, but also genes known for their role in immune system response,
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making them key indicators of any resultant inflammation caused by/in response to the
potential hazardous substance being studied. CX3CL1 is one such gene, and encodes for a
cytokine protein that is also known by the names: neurotactin or fractalkine (FKN)
(Imaizumi, Yoshida, & Satoh, 2004). The importance of the CX3CL1 protein is that it
functions as a transmembrane protein that can be expressed/found on stressed/inflamed
endothelium, dendritic cells, neurons, epithelial cells, and plays a role in adhering and
guiding leukocytes with its important chemoattractant signaling as well as its adhesion
properties (Ancuta et al., 2003; Harrison et al., 1998; Imai et al., 1997; Lucas et al., 2001;
Papadopoulos et al., 1999).
CX3CL1 and its stimulating effects/cooperativeness with immune system response,
in regards to apoptotic cells, has made it useful as an inflammatory marker for diseased
states such as COPD (chronic obstructive pulmonary disease)(Ning et al., 2004).
Expression of CX3CL1 is upregulated in cigarette-smoke induced emphysema, as well as
in response to prolonged tobacco smoke exposure (McComb et al., 2008). When studied
with its ligand receptor, CX3CR1, which has also been seen to be upregulated in
expression, in response to prolonged tobacco smoke exposure, a CX3CL1-CX3CR1
pathway is thought to possibly be a front-runner for recruiting the immune system within
lung tissue when damage has occurred due to cigarette smoke (McComb et al., 2008). We
hypothesize that the study of CX3CL1 expression could also potentially prove it to possibly
be a beneficial marker for lung tissue damage in the setting of e-cigarette exposure as well,
and could shed light into any possibly increased immune response due to tobacco alkaloid
exposure.
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GPX2
One of the ways a diseased state in the lung can be identified is by observing an
increase in the protective enzymes being translated by host machinery to help protect the
cell from damage. One such protective enzyme is a protein produced by the GPX2 gene
(Brigelius-Flohe & Kipp, 2012; Singh et al., 2006). The GPX2 protein is part of a family
of glutathione peroxidases, which are antioxidant enzymes that reduce hydrogen peroxide
and organic hydroperoxides by way of glutathione, and by doing so, help to protect the cell
from acquired oxidative stress (National Center for Biotecnology Information; Singh et al.,
2006). In studies carried out concerning airway gene expression differentiation when
exposed to tobacco smoke in cigarettes, GPX2 showed an irreversible differentiation in
expression (Banerjee et al.; Beane et al., 2007). In another study, GPX2 was seen to be
consistently upregulated in current and former smokers with adenocarcinomas, and could
possibly serve as a biomarker in its upregulated state for lung cancer risk (Woenckhaus et
al., 2006).

ALDH3A1
Along with GPX2, another useful biomarker for visualizing oxidative stress within
the tissues of the lung is upregulation of the ALDH3A1 gene (Gebel et al., 2004;
Woenckhaus et al., 2006). The protein produced by ALDH3A1 belongs to the ALDH
superfamily of proteins, a family of proteins which are known to oxidize aldehydes that
can originate both endogenously and exogenously within the human body, and that can
potentially become hazardous to the human body due to their electrophilic state and
tendency to react with amino and thiol groups, sometimes leading to carcinogenic effects

25

(Vasiliou & Nebert, 2005). Some endogenously formed aldehydes can occur through the
metabolism of lipids, vitamins, and steroids within the body, whereas some exogenously
formed aldehydes may occur through exposure to environmental toxins and ingested
recreational drugs such as tobacco smoke (Vasiliou & Nebert, 2005).
In context as a useful biomarker within this study for determining cytotoxic damage
from tobacco alkaloids, studies have previously found ALDH3A1 to be upregulated within
the respiratory tissue of rats upon exposure to tobacco cigarettes (Gebel et al., 2004).
ALDH3A1 has also been observed as being inducible, if not the most inducible of the ALDH
family, to tobacco cigarette smoke exposure among human airway epithelial cells (Patel et
al., 2008). In its upregulated state among non-small cell lung cancer cells, however, its role
in carcinogenesis is still un-determined, and there is even some evidence linking its
overexpression of its encoded aldehyde dehydrogenase protein to the reduction and
possibly protection of cytotoxicity and DNA damage within the cell due to tobacco
cigarette smoke exposure (Jang et al., 2014; Patel et al., 2008).

PIR
Another gene that is similar to GPX2, in that it has been also shown in studies as
being irreversible in its consequential differential gene expression in response to tobacco
smoke exposure, is the gene PIR (Banerjee et al.). The PIR gene encodes a member of the
cupin protein superfamily, a family of proteins distinguished by their β-barrel fold structure
and from being composed of proteins that are enzymatic as well as proteins that are nonenzymatic (Dunwell, Culham, Carter, Sosa-Aguirre, & Goodenough, 2001). Present in
nearly all mammalian tissue cells, PIR is thought to be involved in DNA transcription and
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regulation through its interaction with nuclear factor I/CCAAT box transcription factor
(NFI/CTF1) as well as its studied interaction with B-cell lymphoma protein, BCL-3, a
regulator of NF-κB/Rel activity (Licciulli et al., 2011; Wendler, Kremmer, Forster, &
Winnacker, 1997). In a study carried out that evaluated PIR expression in melanocytes,
PIR was shown to be a negative regulator of cellular senescence, and so once upregulated,
appears to contribute an oncogenic state (Licciulli et al., 2011). By studying the PIR gene
in response to tobacco alkaloids, we can evaluate whether tobacco alkaloids can induce an
oncogenic state within lung tissue, but within the spectrum of also studying the effects of
e-cigarette use.

CYP1A1
In expanding our investigation into the possible disease initiating/modifying
potential of the tobacco alkaloids found in e-cigarette filling solution, differential response
between gender is also of concern. To study these differences, we investigate expression
within TP53, as mentioned previously, and also CYP1A1, which is also known as aryl
hydrocarbon hydroxylase and a member of the cytochrome P450 superfamily of enzymes
(National Center for Biotechnology Information). The proteins produced by this known
superfamily are responsible in catalyzing reactions involved in drug metabolism as well as
the synthesis of steroids, lipids, and cholesterol (McLemore et al., 1990).
One of the modes of action for CYP1A1 that is of concern, involves the metabolism
of xenobiotics such as polycyclic aromatic hydrocarbons (PAHs) found in tobacco smoke
into

potentially

harmful,

carcinogenic

intermediates,

especially

with

certain

polymorphisms of the gene (McLemore et al., 1990; Nakachi, Imai, Hayashi, & Kawajiri,
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1993; National Center for Biotechnology Information). PAHs are formed by the
combustion of fossil fuels and can be found not only in tobacco cigarettes, but throughout
our environment in various forms such as our soil and even grilled meat (Lee, 2000). Some
PAHs are known to have individual carcinogenic properties, and some PAHs can be
bioactivated to a carcinogenic state by enzymes such as CYP1A1 (Iwano, Asanuma,
Nukaya, Saito, & Kamataki, 2005; Lee, 2000).
Not only has CYP1A1 been shown to metabolize PAHs into harmful, carcinogenic
intermediates, but studies between non-tobacco cigarette smokers and tobacco cigarette
smokers have also shown that PAHs stimulate the production of CYP1A1, indicated by
higher levels of CYP1A1 expression within smokers as opposed to non-smokers
(McLemore et al., 1990). This links CYP1A1 and its upregulation in translation due to
PAHs, to an increase in lung cancer risk, also giving CYP1A1 the potential to be used as a
lung cancer biomarker (McLemore et al., 1990). Interestingly, studies have also shown an
upregulation in CYP1A1 with exposure to the tobacco alkaloid, nicotine, which makes it a
potentially valuable biomarker in this study as well, regarding potential differential gene
expression from e-cigarette use due to the tobacco alkaloids found within the e-cigarette
filling solutions (Michael M. Iba & Fung, 1999; M. M. Iba, Scholl, Fung, Thomas, & Alam,
1998).
In analyzing differences in gene expression among gender, investigation of
CYP1A1 is of benefit due to previous research linking abnormal upregulation of the gene
within female smokers, in comparison to male smokers, as well as an increase in PAH
adduct levels, which have been studied as a contributing factor of an increased
susceptibility to lung cancer (Mollerup et al., 2006; Mollerup, Ryberg, Hewer, Phillips, &
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Haugen, 1999). By studying differences in gene expression among TP53 and CYP1A1
among the male lung tissue cell lines and the female lung tissue cell line within this study,
a correlation, or lack thereof, may help shed light as to whether tobacco alkaloids found
within e-cigarette filling solutions can cause different physical effects between genders.

AHR
In direct relation with CYP1A1, AHR is another gene of interest. As a protein coding
gene, AHR encodes for a transcription factor known to carry out a receptor-ligand activated
response to PAHs (Lin, Hu, & Chang, 2003; National Center for Biotechnology
Information). After activation of the receptor by the ligand, AHR travels from the
cytoplasm of the cell to the nucleus, heterodimerizes with AhR nuclear translocator (Arnt),
and in turn stimulates the transcription of xenobiotic metabolizing enzymes such as
CYP1A1, which was stated previously as a metabolizer of xenobiotics such as PAHs found
in tobacco smoke (Lin et al., 2003; National Center for Biotechnology Information).
With regard to the effects of tobacco alkaloids found in e-cigarettes, investigating
genetic expression of AHR is of interest due to previous evidence that the AHR receptor is
not only activated by PAH ligands, but seems to also be activated by nicotine, due to an
increase in AHR levels being seen when lung fibroblast cells in culture were treated with
the alkaloid (Sohn et al., 2008). This AHR activating CYP1A1 pathway, therefore, would
seem to not only recommend the investigation into the expression levels of both genes
when investigating the potential of an increased carcinogenic state due to the exposure of
PAHs, but also when there has been exposure to the tobacco alkaloid, nicotine.
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CEACAM6
Among the genes that have been previously studied as putative oncogenes in a
setting of tobacco smoke exposure, CEACAM6 has been shown, along with MDM2, PIR,
and CYP1A1, as a top candidate for use as a biomarker in determining lung cancer
susceptibility due to its upregulated state in exposure to cigarette smoke (Beane et al., 2007;
Blumenthal, Hansen, & Goldenberg, 2005; Gonzales et al., 2015; Huang et al., 2010; Spira
et al., 2004). Importantly, this upregulated state has also been shown to be irreversible
(Beane et al., 2007). The protein encoded for by CEACAM6 is a glycosyl phosphatidyl
inositol (GPI) anchored cell surface glycoprotein that belongs to the carcinoembryonic
antigen (CEA) family of proteins (Blumenthal, Leon, Hansen, & Goldenberg, 2007;
Gonzales et al., 2015). The CEACAM6 protein can be found within various epithelium
tissue and has a role in cell differentiation, as well as innate immune response, but its
adhesion and anti-apoptotic properties are of concern due to the speculative role in
facilitating tumor growth and migration within the tissues (such as the lung, gastrointestinal
tract, pancreas, and breast) (Blumenthal et al., 2005; Blumenthal et al., 2007; Gonzales et
al., 2015; Ilantzis, DeMarte, Screaton, & Stanners, 2002). It is also of interest due to its
upregulatory expression seen within the lung tissue of smokers, making it a potential
biomarker for tumorigenesis, and possibly a very beneficial candidate gene to investigate
in regards to the tobacco alkaloids found within e-cigarettes (Huang et al., 2010; Spira et
al., 2004).
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Goals/Aims of Research
In this study, we aim to investigate the effects of tobacco alkaloids found within ecigarette filling solution on lung cell proliferation and gene expression. With electronic
cigarette use on the rise among consumers looking for a safer alternative or drawn in by its
trendy appeal, data concerning the effects of e-cigarette use and the effects of the chemical
compounds that make up its filling solution is still greatly lacking (Pepper et al., 2015;
Surgeon General, 2016). To shed more light on possible health outcomes that could become
associated with e-cigarette use, we have conducted a study focusing on the tobacco
alkaloids: anabasine, cotinine, myosmine, and nicotine, previously found within e-cigarette
filling solution (Trehy et al., 2011). We hypothesize, based on prior research indicating
tobacco alkaloids as contributing factors to diseased states of the human body (Hecht &
Hoffmann, 1988; McBride et al., 1998; Wilp et al., 2002), that these four tobacco alkaloids
have the capability of contributing to differential cell proliferation and abnormal gene
expression with e-cigarette use. In addition to studying the effects of these tobacco
alkaloids on the human body in a broad sense, we aim to also expand our investigation to
include a study on any differences seen among gender and disease status by testing the
alkaloids within this study against a panel of lung tissue cell lines varying in gender
(male/female) and disease status (normal/cancer).
To carry out this investigation into potential differential cell proliferation among
the cell lines, varying alkaloid concentrations are exposed to a panel of cell lines in a 10day time-course, with viability determined through the Promega CellTiter-Glo®
Luminescent Viability Assay. Investigation of gene expression is carried out with the
isolation of RNA from within the alkaloid treated and un-treated cell lines after 48 and 96-
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hour time-points, followed by creation of cDNA samples from those RNA transcripts. The
cDNA samples are then utilized to proficiently quantitate targeted gene expression by way
of quantitative reverse transcription polymerase chain reaction technology (qRT-PCR),
carried out in real time. This process is meant to measure the amount of mRNA transcript
being made by the cell, which is a direct reflection of what proteins are going to be
produced due to specific gene expression. The cDNA synthesized from RNA of control
and treated samples and quantified by qRT-PCR technology, is analyzed for the expression
of 10 candidate genes, chosen due to their potential as a useful biomarker for disease and/or
sex-specific expression. Differential cell proliferation and potential gene expression
abnormalities, due to exposure to the alkaloids mentioned previously, are then evaluated
using statistical methods.

MATERIALS AND METHODS
Description of Cell Lines
Evaluation of cell growth and viability was investigated by treating human lung
cells in culture with varying concentrations of nicotine, cotinine, myosmine, and anabasine.
Cell cultures exposed to the tobacco alkaloids were then compared to non-exposed cell
cultures for analysis of cell growth and viability, as well as differential gene expression.
To examine any differences related to sex specific gene expression in exposure to
electronic cigarettes, as well as any differences related to disease state, a panel of three
different cell lines was utilized, varying in gender (male/female) and disease status
(normal/cancer). The three cell lines used in the panel were: CCL-185, CCL-171, and CCL186, and were purchased from the American Tissue Culture Collection (ATCC) (Manassas,
32

VA) (Table 2). CCL-171 and CCL-186 are normal cell lines capable of senescence, and
CCL-185 is considered a transformed cell line due to its cancerous state, and therefore
considered immortal (Table 2). CCL-171 was documented by the ATCC of being capable
of 42-46 population doublings before the onset of senescence, and CCL-186 was
documented as having 58. CCL-171 was received from ATCC in anticipation of this study
at passage number 16, whereas CCL-186 was received from ATCC at passage number 10.
Table 2: Human Lung Tissue Cell Lines Exposed to Tobacco Alkaloids
ATCC No.

Alternate
Name

Tissue
Type

Organism

Sex

Disease
Status

CCL-185

A549

Lung

Homo sapiens

Male

Carcinoma

CCL-171

MRC-5

Lung

Homo sapiens

Male

Normal

CCL-186

IMR-90

Lung

Homo sapiens

Female

Normal

Tissue Culture Growth and Maintenance
The three lung tissue cell lines that were examined in this study were seeded from
frozen into vented, Falcon® 75 cm2 tissue culture flasks. Cell lines, CCL-171 and CCL186 were cultured in Eagle’s Minimum Essential Growth Medium supplemented with 1.5
g/L sodium bicarbonate, non-essential amino acids, L-glutamine, and sodium pyruvate, and
adjusted to contain an added 10% fetal bovine serum (FBS), used to provide essential and
rich growth factors, as well as 1% penicillin-streptomycin solution, utilized for prevention
of bacterial contamination. Cell line CCL-185 was cultured in HyClone™ DMEM/High
Glucose growth medium containing 4.00 mM L-glutamine, 4500 mg/L glucose, sodium
pyruvate, 10% FBS and 1% penicillin-streptomycin. All cells were maintained within a
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CO2 incubator set at 37˚C and 5% CO2, with media renewal every three days underneath a
laminar flow hood, using aseptic practices.
To prevent contact inhibition and to promote a healthy environment, when the lung
tissue cells in culture reached a confluency of ~70%, the cells were either sub-cultured, to
allow for continued growth, or utilized in the seeding of a 10-day experimental time course.
In either case, media was aseptically removed, and 3 mL of 0.25% trypsin solution was
added into each flask to detach the cells from the tissue culture flask and to promote a
single cell suspension. Cells were incubated within the trypsin solution for no more than 5
minutes until a single cell suspension was reached. Once cells reached a single cell
suspension, they were either split 1:2, 1:3, or 1:5 (depending upon confluency) and seeded
into fresh 75 cm2 flasks containing fresh growth media, or utilized in seeding tissue culture
plates that were to be used for the 10-day experimental time course.

CellTiter-Glo® Luminescent Viability Assay
To examine the effect of alkaloid exposure on cell proliferation, lung tissue culture
samples of CCL-185, CCL-186, and CCL-171 were characterized for growth and viability
in 10-day time course experiments, while exposed to 1 µg/mL, 10 µg/mL, and 100 µg/mL
concentrations of the tobacco alkaloids: anabasine, cotinine, myosmine, and nicotine,
individually. Cell viability was determined daily, relative to untreated controls by using the
Promega CellTiter-Glo® Luminescent Viability assay which relies of a thermostable
luciferase reaction that detects metabolic ATP levels in the cell (Promega Corporation,
2015). The amount of ATP present is directly proportional to the number of cells present
due to the rapid degradation of ATP after cell death. The CellTiter-Glo® luminescent
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reagent works by lysing open the cells, releasing ATP while simultaneously inhibiting
ATPases that would decompose the cellular ATP, and providing a measurable
bioluminescent reaction by interaction of cellular ATP with the light-emitting compounds,
luciferin, and its corresponding oxidizing enzyme, luciferase, as well as other associated
reagents (Promega Corporation, 2015).

Plate Set-up for Time Course
In carrying out this assay, lung tissue cells were seeded at a concentration of 20,000
cells/mL/well in 12-well Falcon® tissue culture plates under experimental and control
conditions. Experimental exposure conditions, performed in technical triplicate, included
1 µg/mL, 10 µg/mL, and 100 µg/mL of either anabasine, cotinine, myosmine, or nicotine,
individually, as well an untreated control of 20,000 cells/mL within cell growth media
alone. Alkaloid dilutions were made from 1 mg/mL stock solutions of anabasine, cotinine,
myosmine, and nicotine. Due to differences within molecular weight of each compound,
the molar concentration of each exposure condition varied slightly across the panel of
alkaloids (Table 3).

Table 3: Experimental Alkaloid Dilutions and Associated Molarity

Stock Solution
Concentration

Molarity

Anabasine

1.00 µg/mL

6.16 µM

Cotinine

1.00 µg/mL

5.68 µM

Myosmine

1.00 µg/mL

6.84 µM

Nicotine

1.00 µg/mL

6.16 µM

Alkaloid
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A plate containing experimental conditions of the four alkaloids, along with a
separate plate of controls, was used for each day, totaling 20 plates for the 10-day time
course (Figure 7). Throughout the 10-day time course, the experimental plates were
maintained in the CO2 incubator at 37˚C and 5% CO2.

Figure 7: 12-Well Tissue Culture Plate-Setup of a Cell Line Under
Experimental Conditions.
Each exposure treatment is evaluated in a technical triplicate. For each
10-day time course, 10 plates were independently seeded on day 1
and sequentially analyzed by proliferation assay throughout the time
course.

Measurement of Daily Cell Proliferation
Cell viability and proliferation was measured daily throughout the time course,
using the Promega CellTiter-Glo® Luminescent Viability Assay, per manufacturer’s
instructions. Briefly, 350µL of cell growth media, without FBS or antibiotics, was added
to each well of the 12-well plates containing the cultured cells. Next, 350µL of CellTiterGlo® reagent was applied to the same wells, immediately producing a visible color change
within the media/cell solution. The experimental plates were then incubated on an orbital
shaker for 10 minutes. Once incubation was complete, each well containing either
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experimental conditions or control was assayed for metabolic ATP by loading each sample,
in triplicate, for each well of the 12-well plate they originated, totaling 9 wells per
experimental condition, onto a 96-well white-walled, reflective plate (Figure 8).
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Figure 8: 96-well Plate Set-up for CellTiter-Glo® Luminescent Viability Assay
Cells were sampled from each well of the 12-well plate used for seeding with experimental alkaloid exposure,
into triplicates, totaling nine wells per experimental condition. The wells in the figure are labelled by the
experimental condition exposure of the cells (in alkaloid concentrations of 1 µg/mL, 10 µg/mL of 100 µg/mL),
as well as the moles of ATP for the ATP standard curve that was included on each plate. A plate control of only
media (no cells or substrate) was also included on each plate.

A no template control, to monitor background luminescence, was also loaded in
triplicate, as well as a standard curve of known ATP concentrations (2 x 10-10, 5 x 10-11, 1
x 10-11, 5 x 10-12 and 1 x 10-12 moles) to extrapolate metabolic ATP levels in samples
(Figure 9). Subsequent reading of the 96-well plate was carried out by a Biotek® Synergy
plate-reader for luminescence detection, and results of cell proliferation from the Promega
CellTiter-Glo® Luminescent Viability Assay were then statistically analyzed in Microsoft
Excel™.
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Figure 9: ATP Standard Curve Generated in Moles of ATP.
To extrapolate metabolic ATP levels in samples, a standard curve of known ATP
concentrations/dilutions of: 2 x 10-10, 5 x 10-11, 1 x 10-11, 5 x 10-12 and 1 x 10-12
moles, was loaded onto the cellular proliferation assay plates in triplicate, and
included equal parts media, the varying dilutions of ATP, and CellTiter-Glo®
reagent.

Statistical Analysis of Alkaloid Exposure on Cellular Proliferation
A two-tailed, 2-sample equal variance student t-test was applied to the cell
proliferation results, to evaluate statistical differences between the mean value of each
experimental condition, against the mean value of the untreated control wells. P-values
obtained from the student t-test highlighted the difference in values obtained between
groups (control and experimental) compared to the difference in value obtained within
groups. A p-value cutoff of ≤ 0.05, between experiment and controls, was considered
statistically significant. A p-value obtained that was ≤ 0.05 was accepted as being against
the null hypothesis that any differentiation seen between the experimental value and the
control was due to random chance. Any p-value > 0.05, for the experimental conditions,
was accepted as probable evidence that any differentiation between the experimental

38

conditions and the control was due to random chance, and thus, the null hypothesis was
accepted.
To account for inherent differences in cell proliferation across cell lines, all
experimental values were normalized to the untreated control using the following equation:

% Change = (

𝐄𝐱𝐩𝐞𝐫𝐢𝐞𝐦𝐞𝐧𝐭𝐚𝐥−𝐂𝐨𝐧𝐭𝐫𝐨𝐥
𝐂𝐨𝐧𝐭𝐫𝐨𝐥

) ×𝟏𝟎𝟎

Equation 1: Equation of Percent Change for Normalization of Data to Control

Evaluation of Differential Expression of Candidate Genes by qRT-PCR
Differential gene expression patterns were analyzed by qRT-PCR for each cell line
under untreated and treated conditions, to evaluate the effect of alkaloid exposure on the
expression of a panel of candidate genes speculated to be important in pathology of
tobacco-associated disease (Table 1). The experimental method of qRT-PCR relies on
fluorescent dye technology to indirectly quantify the amount of mRNA transcript in a
sample through specific PCR amplification of target genes that, in the presence of
intercalating dyes, fluoresce when bound to double-stranded DNA product, SYBR green.
Visualization, in real time, of the amplified product, gives the ability to evaluate by
quantitative analysis, a necessary component in comparing our experimental RNA
transcripts against the control, RNA transcripts. There are four basic steps to qRT-PCR:
RNA isolation, cDNA synthesis by reverse transcription, SYBR green, and real-time PCR
and quantitative analysis relative to a standard curve of known concentration values.
Differential gene expression patterns associated for tobacco alkaloid exposure were
evaluated for each cell line at 48 and 96 hours, post treatment. Towards this goal, the three
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different lung cell lines, CCL-185, CCL-186, and CCL-171, were seeded at a density of
20,000 cells/mL into 75cm2 Falcon® tissue culture flasks for a total volume of 19 mL (cells
+ media), and exposed to the tobacco alkaloids in concentrations of either 1µg/mL, 10
µg/mL, or 100 µg/mL. A control consisting of a cell suspension of each cell line that had
not been treated by alkaloids was also seeded simultaneously.

Isolation of RNA from Cell Lines
The QIAGEN® RNeasy RNA Isolation kit was used to isolate total RNA from all
experimental and control samples per manufacturer’s instructions. Briefly, cells were
detached from tissue culture flasks by trypsination, followed by application of cell
suspension to the supplied QIA shredder column, which results in homogenization and
lysis of cells. Genomic DNA was then removed with use of a gDNA eliminator spin
column, provided by the manufacturer. Ethanol was added to the total RNA, and the
suspension was then passed through the manufacturer provided RNeasy spin column, that
binds the RNA to the filter. The column was then washed twice before the total RNA was
eluted from the column with 30 µL of nuclease-free water.
RNA isolated was quantified using the Thermo Scientific™ Nanodrop™ and
analyzed for integrity through native agarose gel electrophoresis (Figure 10) that was
prepared with RNase free reagents and consisted of RNase free agarose at a 1.2%
concentration. The native agarose gel was then electrophoresed in RNase free 1X TBE
buffer, and ran at ~ 5-6 Volts/cm, until the bromophenol blue that was added to the RNA
samples had migrated to approximately a third of the way down the gel. The gel was then
visualized under a UV transilluminator for the presence/absence of contaminating genomic
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DNA, as well as visualization of the clarity and sharpness of the 28S and 18S eukaryotic
rRNA bands within the total RNA samples (Figure 10).

Wells

28S rRNA

18S rRNA

Figure 10: Evaluation of RNA Integrity and Purity by Native Agarose Gel Electrophoresis
Isolated RNA samples were run through agarose gel electrophoresis to evaluate for purity, which is the
absence of contaminating genomic DNA, and for integrity, which is evaluated by observing the
presence of rRNA bands. The presence of fluorescence near the wells of the gel can indicate
contaminating genomic DNA that resides higher in the lanes due to the higher molecular weight. Bands
are also analyzed for their sharpness in determining integrity of the sample. In eukaryotic cells, sharp
bands should be present for both the 28S and the 18S ribosomal subunits, with the band for the 28S
appearing twice as intense as the 18S.

Complimentary DNA (cDNA) Synthesis by Reverse-Transcription
For analysis of differential gene expression by qRT-PCR, isolated experimental
RNA was converted to complementary DNA (cDNA) with the Bio-Rad iScript™ Reverse
Transcription Supermix for qRT-PCR. cDNA synthesis was carried out by following the
manufacturer’s protocol for a 40 µL cDNA reaction (Table 4), and programmed for the
following thermal cycler settings: priming of the template at 25˚C for 5 minutes, reverse
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transcription at 42˚C for 30 minutes, and inactivation of reverse transcriptase at 85˚C for 5
minutes.
Table 4: Bio-Rad Protocol for 40 µl cDNA Reaction

Reagent

Volume

Bio-Rad iScript™ Reverse
Transcription Supermix *

8 µL

Experimental total RNA sample

2 µg
varying**

Nuclease-free water
Total Volume = 40 µL

*Bio-Rad iScript™ Reverse Transcription Supermix includes: reverse transcriptase, RNase inhibitor,
dNTPs, oligo(dT), random primers, buffer, MgCl2, and stabilizer.
**Nuclease-free water added to bring the reaction up to 40 µL/reaction.

SYBR Green Real-Time PCR
Description of Candidate Genes and Primer Design
Analysis of gene expression by qRT-PCR was carried out by using markers
targeting specific candidate genes speculated to be important in pathology of tobaccoassociated disease. Table 1 summarizes the ten candidate genes selected and their focused
function for gene expression analysis. Two reference genes (also known as housekeeping
genes) were also utilized within this study as a reference to normal cell function and
metabolism that should be seen, regardless of the different experimental conditions
imposed.
To isolate the candidate genes within experimental cDNA template as well as to
create gene standards for a standard curve, primers to amplify their target sequence in a
polymerase chain reaction were designed through idtDNA (Integrated DNA Technologies,
2017) and purchased through the companies Eurofins Genomics and Invitrogen. The
parameters for design of forward and reverse primers were set to amplify across exon: exon
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junctions, generate a product size in the range of 75-150 bps, be matched for % G/C and
annealing temperatures between 55 - 65°C, and have minimal primer: dimer and selfannealing properties. Each validated primer pair used yielded a single peak of dissociation
upon melting curve analysis. Primer sequences designed are listed in Table 5.

Table 5: Candidate Genes to Be Evaluated for Differential Gene Expression and their Designed
Primers
Gene Symbol

Primer Sequence

Mature Amplicon
Length

Genomic
Amplicon Length

AHR

5’-TCATTGTAACTCAGAGACCACTAAC-3’
5’-CATTATGGCAGGAAAAGGGTTG-3’

137 bp

3,336 bp

ALDH3A1*

5’- CCTTAAATACGTCCCCTCTTGG-3’
5’- TCGCTGATCTTGCTCATGG-3’

92 bp

3,216 bp

PIR*

5’-AGTAAGGATGGTGTGACAGTTG-3’
5’-AGGGATAGGTTGGGAATGTTTG-3’

135 bp

29,992 bp

CEACAM6*

5’-CTACAAAGAGGTGGACAGAGAAG-3’
5’-AATAGTGAGCTTGGCAGTGG-3

149 bp

996 bp

CX3CL1*

5’-CACCTTCTGCCATCTGACTG-3’
5’-TGCCTGGTTCTGTTGATAGTG-3’

130 bp

7,125 bp

CYP1A1*

5’-CCCAACCCTTCCCTGAATG -3’
5’-TTCTCCTGACAGTGCTCAATC-3’

146 bp

701 bp

MDM2

5’-TGCCAAGCTTCTCTGTGAAAG-3’
5’- TCCTTTTGATCACTCCCACC-3’

148 bp

7,639 bp

SLIT1*

5’–GACTGGCTACAAGGAACCG-3’
5’-TGGACAAGCAGAGATCACAC-3’

149 bp

2, 291 bp

TP53

5’-CCTCAGCATCTTATCCGAGTG -3’
5’- ACATGTAGTTGTAGTGGATGGTG-3’

143 bp

710 bp

GPX2*

5’-GCTTCCCTTGCAACCAATTTG-3’
5’-TTCTGCCCATTCACCTCAC-3’

139 bp

2,805 bp

ACTB*

5’-GGCCGCGGTGTACCAACACAGTGCTG-3’
5’-CCCGGGGCCGTCACTCTGCTTGCTG-3’

225 bp

319 bp

GAPDH*

5’-CCTCAACGACCACTTTGT-3’
5’-TGGTCCAGGGGTCTTACT-3’

116 bp

220 bp

* Primers previously designed by Max Marlowe and/or provided by Dr. Margaret Kovach

Determination of Reference Gene Expression Stability
The two reference genes chosen for this study were selected by testing untreated
and treated experimental samples of the three cell lines: CCL-185, CCL-186, and CCL171, for 14 candidate reference/housekeeping genes by qRT-PCR, using the Bio-Rad
Reference Genes H96 predesigned 96-well panel for use with SYBR® green technology.
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Using the Bio-Rad CFX Connect software, the candidate reference genes tested were
ranked individually for their associated M-value, with an M-value < 0.5 being indicative
of greater gene stability among both the treated and untreated samples and favored as
opposed to those reference genes tested simultaneously with a resultant higher M-value
(Hellemans, Mortier, De Paepe, Speleman, & Vandesompele, 2007). The housekeeping
genes, GAPDH and ACTB, ranked as the reference genes with two of the lowest M-values
and were subsequently both chosen to be reference genes utilized for normalization of gene
expression throughout this study.

Preparation of a Standard Curve
Each of the candidate genes listed in Table 5 were amplified by polymerase chain
reaction to synthesize PCR product of known concentration for use in generating a standard
curve for qRT-PCR analysis of gene expression within the experimental samples. The
reactions for the synthesis of the gene standards included the reagents and volumes outlined
by New England BioLabs® for their Hot Start Taq 2X Master Mix protocol for routine
PCR (Table 6), amplified to create a 5x reaction, and synthesized by polymerase chain
reaction in a thermal cycler set to the following: 1 cycle of initial denaturation at 95˚C for
5 minutes, followed by 40 cycles at 95˚C for 30 seconds (denaturation), 58˚C for 30
seconds (annealing), and 72˚C for 1 minute (extension), and then final extension was
carried out with 1 cycle at 72˚C for 7 minutes.
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Table 6: New England BioLabs® Hot Start Taq 2X Master Mix PCR Reaction Protocol
Reagent

Volume

Hot Start Taq 2x Master Mix*

12.5 µL

Template DNA

< 1,000 ng

Candidate Gene Forward Primer

0.2 µM

Candidate Gene Reverse Primer

0.2 µM

Nuclease-free Water

varying**
Total Volume = 25 µL

*Hot Start Taq 2x Master Mix includes: Hot Start Taq DNA Polymerase, dNTPs, Standard Taq
Reaction Buffer, and stabilizers
**Nuclease-free water added to bring the reaction up to 25 µL/reaction.

Once gene standards were amplified, the synthesized product was loaded onto a 2%
native agarose gel for electrophoresis with 1X TBE buffer. The agarose gel was then
visualized under a UV transilluminator and PCR products of size appropriate to the target
gene mature amplicon length (Table 5), were extracted, and purified using the QIAGEN
Gel Extraction Kit, followed by quantification by Nanodrop™. A solution with 2 x 1010
copies of product per microliter was prepared. This solution was serially diluted tenfold to
prepare a standard curve of DNA with concentrations ranging from 2 x 1010 to 2 x 102
copies of product per microliter. If each reaction performed near 100% efficiency (DNA
doubling in count per cycle), then the linear relationship derived from the standard curve
can be used to predict the copy number in samples of unknown copy number.

qRT-PCR
In order to carry out quantification by qRT-PCR, cDNA derived from
corresponding RNA isolated from control and treated samples, served as template for
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amplification of the candidate genes listed in Tables 1 and 5, as well as the reference genes,
ACTB and GAPDH. Each reaction was carried out in triplicate for each experimental
condition/per cell line with the reagents/volumes listed in Table 7.

Table 7: Bio-Rad 2x iQ™ SYBR Green Supermix Reaction Protocol
Reagent

Volume

2X iQ™ SYBR® Green Supermix *

12.5 µL

Template DNA

1 µg

Candidate Gene Forward Primer

10 pmol (of a 20 pmol/µL stock working solution)

Candidate Gene Reverse Primer

10 pmol (of a 20 pmol/µL stock working solution)

Nuclease-free Water

varying**
Total Volume = 25 µL

*2X iQ™ SYBR® Green Supermix is brought to a final concentration of 1X by addition of reagents
listed.
**Nuclease-free water added to bring the reaction up to 25 µL/reaction.

Each 25 µL reaction was then loaded onto a 96-well plate (each experimental
condition, for each cell line, in triplicate) along with a no template control (NTP), a no
primer control (NPC), and an interplate control (IPC), each loaded in duplicate. The 96well plate also contained standard dilutions of the gene being analyzed for that specific
plate to test for efficiency of the candidate gene primers. The standards ranged in copy
numbers of 1 x 108 to 1 x 102, with each standard being loaded onto the plate in duplicate.
The layout of the 96-well plate is illustrated in Figure 11. The 96-well plate, once loaded,
was then subject to real time qRT-PCR by the Bio-Rad CFX Connect Real-Time PCR
detection system.
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Figure 11: qRT-PCR Plate Lay-out for Gene Expression Analysis of Cells Lines Exposed to Tobacco
Alkaloids.
Legend: NTC= No template control; NPC= No primer control; IPC= Interplate control

Statistical Analysis of Quantitative Reverse-Transcription PCR Data
In evaluating gene expression by qRT-PCR, the target sequence of the gene can be
analyzed with fluorescent technology in real-time, by observing the pace at which the
fluorescent signal of the target sequence reaches a detection threshold, which is then
charted out onto a graph for analysis (Figure 12). The threshold cycle number (Ct) is the
number at which the signal of the targeted sequence reaches the threshold. The threshold
cycle number can then be used to calculate the quantity of the initial sample copies since
the Ct is inversely related to the amount of starting material. When the sample reaches the
threshold, the cycle number recorded is used to calculate the difference between starting
material, by factoring in that the material approximately doubles after every cycle. So, a
sample passing the threshold at cycle number 10, in comparison to a sample passing the
threshold at cycle number 20, would correlate to a 210 difference between the two samples
since the cycles reached their respected thresholds ten cycles apart from each other.
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A

B

C

Fluorescence
threshold

Figure 12: qRT-PCR Quantification of Gene Expression for Analyzation of Isolated RNA Under
Varying Conditions.
The Y-axis of the graph represents the relative fluorescence, and the X-axis represents the cycle number
associated with that amount of fluorescence. The green horizontal line going directly across the graph
represents the threshold for detecting fluorescence. The Ct values, indicated by arrows, for the
represented samples A, B, and C are 14, 19 and 23, respectively. Thus, in this example there is a 25 (32fold) difference in expression between samples A and B, and a 29 (512-fold) difference in expression
between samples A and C.

Differential gene expression among the experimentally treated cell lines was
evaluated by utilizing the gene expression analysis profile tool in the Bio-Rad CFX
Connect Real-Time PCR Detection software program. The two reference genes, ACTB and
GAPDH, were also analyzed for every cell line tested under the varying experimental
conditions, and the data from these qRT-PCR plates for reference gene expression was then
used to normalize the experimental expression values that were obtained for the other
candidate genes listed by way of the gene expression analysis tool. The efficiency of the
gene standard curve, also loaded onto the experimental plate, was used as well to determine
efficiency within calculations of the gene expression analysis.
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RESULTS
Evaluation of Tobacco Alkaloid Exposure on Lung Cell Proliferation
The effect of tobacco alkaloid exposure on lung cellular proliferation and viability
was examined across cell lines that differed with respect to gender and disease status of
tissue. Three lung tissue cell lines were included in this study: CCL-171, a male, normal
lung tissue cell line, CCL-186, a female, normal lung tissue cell line, and CCL-185, a male,
transformed lung tissue cell line (Table 2). Each lung tissue cell line in the panel displayed
a characteristic growth curve unique to that cell line and differing between the other cell
lines within the panel (Figure 13).

Figure 13: Cell Growth Patterns of Experimental Cell Lines.
The lung tissue cell lines used in this study are characterized in the above graph by their
cell growth curve, when untreated for experimental conditions, for comparison between
cell lines. Three wells of a 12-well tissue culture plate were seeded, without exposure to
any alkaloids, for each time point of a ten-day time course, and for each individual cell line.
The cells were analyzed by the CellTiter-Glo® Luminescent Viability Assay, and the mean
was obtained. The above figure is a graph that depicts the average growth rate of these
cells, per day, given by mols of ATP detected, for the 10-day time course.
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These cell lines were then exposed individually to the tobacco alkaloids: anabasine,
cotinine, myosmine, and nicotine, found to be within e-cigarette filling solutions, in 1
µg/mL, 10 µg/mL, and 100 µg/mL concentrations, over a period of 10 days, and effects on
cell proliferation were then evaluated by utilizing the Promega CellTiter-Glo®
Luminescent Viability Assay every 24 hours, over the course of the 10-day study. An
equation of percent difference to control (Equation 1) was applied to the resultant
experimental data from the cell proliferation assays, to normalize the data to the control.
Results obtained that were greater than or equal to a 25% change from control, and with a
p-value ≤ 0.05, obtained through the two-tailed student t-test, were considered significant
findings and are highlighted in this section.

Anabasine
Overall, the effect of anabasine exposure on lung cell proliferation demonstrated
an inhibitory dose-response, associated with increasing concentration of the alkaloid.
Anabasine exposure to the panel of lung tissue cell lines, in the concentration of 1 µg/mL,
showed minimal change in cellular proliferation to control throughout the 10-day time
courses, with a percent difference to the control (Equation 1) being greater than or equal to
25% only occurring at two time points within the study: an increase in cellular proliferation
of 27.2% on day 1 for the normal, male cell line, and a decrease in cellular proliferation of
26.3% on day 5 for the cancerous cell line.
However, with exposure to higher concentrations of anabasine, there was a more
pronounced effect on proliferation profile across all cell lines, particularly at the highest
exposure concentration (100 µg/mL). The effect varied slightly between stimulatory and
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inhibitory, but ultimately the predominant effect displayed was that of inhibition of cellular
growth. Exceptions to this inhibitory effect of anabasine was observed only in the normal
male cell line, in which an increase of 48.2 % was observed on day 10 of the study, upon
exposure to 10 µg/mL anabasine (Figure 14).
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Figure 14: Cell Growth with Exposure to 10 µg/mL Anabasine, Normalized to Control.
Data obtained daily on the three experimental cell lines, under the exposure of anabasine at
the 10 µg/mL concentration, by the CellTiter-Glo® luminescent viability assay, was normalized
to the control by applying an equation of percent difference for each time-point within the 10day time course. Most significant values within the cell lines are marked by an asterisk (*).
The legend indicates the associated colors for the three varying cell lines: normal male = CCL171, normal female = CCL-186, and cancerous male = CCL-185.

The other time points studied for the individual cell lines, at the 10 µg/mL and 100
µg/mL concentrations, showed a predominately inhibitory effect, with the greatest percent
difference to control, regarding inhibition being displayed, being seen within the normal,
female cell line, as well as the cancer cell line. The normal, female cell line was observed
to display the greatest decrease in cell growth, when compared to control, of 57.6%, when
exposed to 100 µg/mL anabasine, for day 6 (Figure 15). The cancer cell line was observed
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to display its greatest decrease in cellular growth, when exposed to 10 µg/mL anabasine,
on day 6, where there was a decrease in cellular growth, when compared to control, of
52.6% (Figure 14).
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Figure 15: Cell Growth with Exposure to 100 µg/mL Anabasine, Normalized to Control.
Data obtained daily on the three experimental cell lines, under the exposure of anabasine at
the 100 µg/mL concentration, by the CellTiter-Glo® luminescent viability assay, was
normalized to the control by applying an equation of percent difference for each time-point
within the 10-day time course. Most significant values within the cell lines are marked by an
asterisk (*). The legend indicates the associated colors for the three varying cell lines: normal
male = CCL-171, normal female = CCL-186, and cancerous male = CCL-185.

Cotinine
Similar to the findings observed for the effect of anabasine exposure on lung cell
proliferation, cotinine exposure demonstrated minimal effect at the lowest concentration.
Only two time-points, with a percent difference to the control (Equation 1) being greater
than or equal to 25%, occurred within the study: an increase in cellular proliferation of
25.1% on day 1 for the normal male cell line, and an increase in cellular proliferation of
36.7% on day 7 for the cancer cell line.
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The greatest effect of cotinine was observed at the 10 µg/mL concentration, and
interestingly, this effect was inhibitory and specific to the cancer cell line. The greatest
percent difference to control for the cancer cell line was observed on day 7, with a decrease
of cell growth by 69.0% (Figure 16). In contrast, cotinine exposure of the normal lung cell
lines, both CCL-186 and CCL-171, showed a stimulatory effect on cellular growth, where
the greatest percent difference to control for the two cell lines was portrayed by the normal,
male cell line, on day 10, with an increase in cell growth of 52.2% (Figure 16).
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Figure 16: Cell Growth with Exposure to 10 µg/mL Cotinine, Normalized to Control.
Data obtained daily on the three experimental cell lines, under the exposure of cotinine at the
10 µg/mL concentration, by the CellTiter-Glo® luminescent viability assay, was normalized to
the control by applying an equation of percent difference for each time-point within the 10-day
time course. Most significant values within the cell lines are marked by an asterisk (*). The
legend indicates the associated colors for the three varying cell lines: normal male = CCL-171,
normal female = CCL-186, and cancerous male = CCL-185.

Upon exposure to 100 µg/mL cotinine, the effect on proliferation was less
pronounced and only significant after long exposure periods. The normal, male cell line
displayed the greatest increase in cell growth, with an increase of 37.6%, on day 10 of the
study (Figure 17). The female cell line showed just a slight decrease in cell growth, with
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the greatest percent difference to control being a 28.4% decrease, observed on day 9 (Figure
17). The cancer cell line displayed both inhibitory and stimulatory results on cell growth
with 100 µg/mL cotinine. The greatest percent difference to control was a 30.4% increase
in cell growth on day 8 (Figure 17).
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Figure 17: Cell Growth with Exposure to 100 µg/mL Cotinine, Normalized to Control.
Data obtained daily on the three experimental cell lines, under the exposure of cotinine at the
100 µg/mL concentration, by the CellTiter-Glo® luminescent viability assay, was normalized to
the control by applying an equation of percent difference for each time-point within the 10-day
time course. Most significant values within the cell lines are marked by an asterisk (*). The
legend indicates the associated colors for the three varying cell lines: normal male = CCL-171,
normal female = CCL-186, and cancerous male = CCL-185.

Myosmine
Of all the alkaloids tested in this study, myosmine exposure resulted in the most
negative and detrimental effect on lung cell proliferation. In fact, exposure was tolerated
only at the 1 µg/mL and 10 µg/mL concentrations. Exposure at the highest concentration
level (100 µg/mL) demonstrated complete cytotoxicity. Specifically, at the lowest exposure
level, minimal changes in cell proliferation were seen, except after prolonged exposure of

54

the cancer cell line. On the days resulting in the greatest percent difference to control, the
cancer cell line increased in cellular proliferation values by 36.8% on day 9, and 56.1% on
day 10.
Exposure to 10 µg/mL myosmine demonstrated strikingly different effects on
cellular proliferation, characteristic of each cell line. The female cell line was characterized
by a decrease in cellular proliferation, when compared to control, of more than 25%
throughout the length of the 10-day time course, with the greatest percent difference to
control observed on day 7, when a 44.2% decrease was recorded (Figure 18).
In contrast, the normal, male cell line, displayed a biphasic growth curve,
characterized by an inhibitory effect during the first phase, with the greatest percent
difference to control being obtained at 30.7%, on day 4, followed by a stimulatory effect
on cellular proliferation for the remaining five days of the 10-day study, with the greatest
percent difference to control on day 10, at 46.9% (Figure 18).
Lastly, cancer cell line, showed a strong stimulatory effect on cellular growth
during the first five days of exposure, with the maximum increase of 138% observed on
day 1, but returned to relatively normal growth for the remaining length of the 10-day study
(Figure 18).
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Figure 18: Cell Growth with Exposure to 10 µg/mL Myosmine, Normalized to Control.
Data obtained daily on the three experimental cell lines, under the exposure of myosmine at
the 10 µg/mL concentration, by the CellTiter-Glo® luminescent viability assay, was
normalized to the control by applying an equation of percent difference for each time-point
within the 10-day time course. Most significant values within the cell lines are marked by an
asterisk (*). The legend indicates the associated colors for the three varying cell lines: normal
male = CCL-171, normal female = CCL-186, and cancerous male = CCL-185.

At 100 µg/mL, the toxicity of myosmine completely inhibited all cellular growth,
for all three lung cell lines, by day 3 of the 10-day study. Associated p-values for the three
cell lines correlated with this extreme decrease in cell viability, with the p-values for each
time point, and for every cell line, being greatly under the 0.05 threshold of significance
(Figure 19).
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Figure 19: Cell Growth with Exposure to 100 µg/mL Myosmine, Normalized to Control.
Data obtained daily on the three experimental cell lines, under the exposure of myosmine at
the 100 µg/mL concentration, by the CellTiter-Glo® luminescent viability assay, was normalized
to the control by applying an equation of percent difference for each time-point within the 10day time course. There was a complete loss of cell viability among all three cell lines by day 3.
The legend indicates the associated colors for the three varying cell lines: normal male = CCL171, normal female = CCL-186, and cancerous male = CCL-185.

Nicotine
Surprisingly, the most well-known of the tobacco alkaloids, nicotine, exhibited the
most varied response upon exposure to the panel of lung tissue cell lines, with no real trends
observed in stimulation or inhibition of cell growth. Similar to anabasine and cotinine, the
lowest concentration showed minimal change in cellular proliferation to control throughout
the 10-day time courses, with no significant values in cellular growth obtained. Exposure
to the higher concentrations (10 µg/mL and 100 µg/mL), however, displayed a variant
effect on the lung cell lines.
Within the normal, female cell line, this variance was observed upon exposure to
10 µg/mL nicotine as a biphasic effect on cell growth, with a decrease observed during the
first five days of the 10-day time course, and then an increase in cell growth towards the
last five days. The greatest percent difference to control for the female cell line, regarding
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a decrease in cell viability, was recorded on day 2, with a decrease of 26.7%, and the
greatest increase in cell growth was recorded on day 9, with an increase of 30.7% (Figure
20).
In contrast, the normal, male cell line displayed fewer significant changes upon
exposure to 10 µg/mL nicotine, where only a slight stimulatory effect was noted for the
last six days of the 10-day time course (Figure 20). The greatest percent difference to
control within the 10-day time course for the male cell line was recorded on day 10, where
there was an increase in cell growth of 27.8% (Figure 20). The cancer cell line, however,
showed a more significant stimulatory response upon exposure to 10 µg/mL nicotine, with
the greatest percent difference to control observed on day 1 of the 10-day time-course, with
an increase in cellular growth at a remarkable 166% (Figure 20).
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Figure 20: Cell Growth with Exposure to 10 µg/mL Nicotine, Normalized to Control.
Data obtained daily on the three experimental cell lines, under the exposure of nicotine at
the 10 µg/mL concentration, by the CellTiter-Glo® luminescent viability assay, was
normalized to the control by applying an equation of percent difference for each time-point
within the 10-day time course. Most significant values within the cell lines are marked by
an asterisk (*). The legend indicates the associated colors for the three varying cell lines:
normal male = CCL-171, normal female = CCL-186, and cancerous male = CCL-185.
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Finally, at the 100 µg/mL concentration of nicotine exposure, the normal, female
cell line displayed variance once more, by showing little to no effect within cellular growth.
The cancer cell line, also continued this trend of variance by portraying a decrease in
cellular growth upon exposure to the highest concentration. The most profound decrease
within the cancer cell line occurred on day 1 of the study, where a decrease in percent
difference when compared to control was recorded at 56.7% (Figure 21). In contrast, the
normal, male cell line, did not display variance but continued to display a slight stimulatory
effect in cell growth from exposure to nicotine at the 100 µg/mL concentration. On day 10,
the normal male cell line exhibited the greatest increase in cell growth, recorded at 46%
(Figure 21).
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Figure 21: Cell Growth with Exposure to 100 µg/mL Nicotine, Normalized to Control.
Data obtained daily on the three experimental cell lines, under the exposure of nicotine at
the 100 µg/mL concentration, by the CellTiter-Glo® luminescent viability assay, was
normalized to the control by applying an equation of percent difference for each time-point
within the 10-day time course. Most significant values within the cell lines are marked by
an asterisk (*). The legend indicates the associated colors for the three varying cell lines:
normal male = CCL-171, normal female = CCL-186, and cancerous male = CCL-185.
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Expression of Candidate Genes by qRT-PCR
To evaluate candidate gene expression patterns among the alkaloid treated and untreated cell cultures, control and alkaloid-treated, experimental samples of the lung tissue
cell lines were analyzed by qRT-PCR, for seven candidate genes listed within Table 1. Due
to loss of cell viability, experimental RNA samples of the cell lines treated with myosmine,
at the 100 µg/mL concentration, were unattainable, and therefore gene expression analysis
was not carried out for experimental samples treated with myosmine, at any of the alkaloid
concentrations or time points. Also, due to time constraints and funding, as well as little
variance being observed on cell proliferation and viability, the experimental samples that
were exposed to only a 1 µg/mL concentration of the four alkaloids, were excluded from
gene expression analysis. Of the experimental samples that could be analyzed, expression
levels that displayed a 4-fold increase or decrease, along with a correlating p-value of ≤
0.01, were evaluated as statistically significant. Three candidate genes: PIR, CX3CLI, and
SLIT1, listed in Table 1, were unable to be analyzed due to either unsatisfactory binding of
designed primers and/or low expression levels, as noted in Table 1.

Anabasine
The most significant effect seen on differential expression within candidate genes
from exposure to the alkaloids, was seen from exposure to anabasine. Upon exposure to
the anabasine, at different concentrations, an upregulation of gene expression was observed
for many of the candidate genes, which were chosen due to their usefulness as biomarkers
for cytotoxic damage and carcinogenesis. Notably, this upregulatory effect was also seen
across all cell lines.
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Upon exposure to 10 µg/mL anabasine, the normal, male cell line, showed no
significant change in expression levels of the seven candidate genes analyzed (Table 1,5),
however, the cancer cell line displayed an upregulatory response in gene expression for the
candidate genes: AHR, ALDH3A1, CEACAM6, CYP1A1, and GPX2, at the 96-hour time
point. The most significant increase in expression seen within the cancer cell line was in
ALDH3A1, where a 19.3-fold increase was observed, when normalized to the control. The
normal, female cell line also displayed this upregulatory response in expression as well,
for the candidate genes: ALDH3A1, CEACAM6, GPX2, and TP53, at the 48-hour time
point. Within the normal, female cell line, the highest increase in expression was also
observed in ALDH3A1, where there was a 6.81-fold increase in expression when
normalized to the control.
Figure 22 presents a volcano plot summarizing the significant findings from the 10
µg/mL exposure on the cell lines. Though differentially expressed genes, CEACAM6 and
GPX2, common to both the normal, female cell line and the cancer cell lines are highlighted
within the plot together, AHR, also highlighted within the plot, was only differentially
expressed within the cancer cell line. The volcano plot can quickly be interpreted for gene
expression relative to control by visualizing any plot to the right of the vertical, green dotted
line as at least a + 4.0-fold change in expression for that gene, and any plot to the left of
the vertical, red dotted line as at least a – 4.0-fold change in expression for that gene.
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Differential Gene Expression When Exposed to Anabasine at
10 µg/mL
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Figure 22: Relative Normalized Gene Expression with Exposure to Anabasine at 10µg/mL.
Data obtained at 48 hours and 96 hours, on the three experimental cell lines, under the exposure
of anabasine at the 10 µg/mL concentration, was analyzed by qRT-PCR for differential gene
expression of seven candidate genes. Only cell lines displaying significant differential expression
of candidate genes are shown. Values obtained for CCL-185 were obtained at the 96 hr time-point,
and values obtained for CCL-186 were obtained at the 48 hr time-point. Legend: Blue horizontal
line= p-value threshold of 0.01; Red vertical dotted line= -4.0-fold change in expression and green
vertical dotted line= +4.0-fold change in expression, any gene expression data lying in between
the two values was evaluated as insignificant; Green transparent oval= indicative of data for CCL185; Red transparent rectangle= indicative of data for CCL-186.

Following the normal, female cell line and cancer cell line, at 100 µg/mL anabasine
exposure, the normal male cell line also started to display significant upregulation within
the candidate genes serving as disease biomarkers. An upregulatory response in expression
of ALDH3A1, CEACAM6, CYP1A1, GPX2, MDM2, and TP53, was seen in the normal
male cell line at the 48-hour time point (Figure 23), with GPX2 evaluated as having the
highest increase in expression, displaying a 15.8-fold increase, when normalized to the
control. The normal female cell line, when exposed to 100 µg/mL anabasine, showed a
surprising downregulatory response in expression of MDM2 at the 48-hour time point, with
a -4.70-fold decrease in expression recorded, when normalized to the control.
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Lastly, the cancer cell line showed insignificant changes in expression within the
seven candidate genes (Table 1) upon exposure to 100 µg/mL anabasine. Significant
findings in differential gene expression, after exposure to 100 µg/mL anabasine, are
featured within the volcano plot, Figure 23, listed below, where there was no common
upregulation or downregulation seen within the either the normal, female or normal, male
cell lines.
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Figure 23: Relative Normalized Gene Expression with Exposure to Anabasine at
100µg/mL.
Data obtained at 48 hours and 96 hours, on the three experimental cell lines, under the
exposure of anabasine at the 100 µg/mL concentration, was analyzed by qRT-PCR for
differential gene expression of seven candidate genes. Only cell lines displaying significant
differential expression of candidate genes are shown. All values obtained for CCL-171 and
CCL-186 were obtained at the 48 hr time-point. Legend: Blue horizontal line= p-value
threshold of 0.01; Red vertical dotted line= -4.0-fold change in expression and green vertical
dotted line= +4.0-fold change in expression, any gene expression data lying in between the
two values was evaluated as insignificant; Blue transparent oval= indicative of data for CCL171; Red transparent oval= indicative of data for CCL-186.

Cotinine
In contrast to anabasine exposure, lung cells exposed to cotinine at varying
concentrations showed limited findings, with the only significant upregulation in gene
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expression seen within the cancer cell line. Upon exposure to 10 µg/mL cotinine, the
normal, male cell line, and the normal, female cell line, displayed no significant changes
in the seven candidate genes analyzed (Table 1). The cancer cell line displayed an
upregulatory response, at the 48-hour time-point, in AHR, ALDH3A1, CYP1A1, GPX2,
MDM2, and TP53. The greatest increase in expression was seen in ALDH3A1, displaying
a 15.1-fold increase in expression, when normalized to the control. Figure 24 depicts these
significant values for differential gene expression within the cancer cell line, below.
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Figure 24: Relative Normalized Gene Expression with Exposure to Cotinine at
10µg/mL.
Data obtained at 48 hours and 96 hours, on the three experimental cell lines, under the
exposure of cotinine at the 10 µg/mL concentration, was analyzed by qRT-PCR for
differential gene expression of seven candidate genes. Only cell lines displaying significant
differential expression of candidate genes are shown. All values obtained for CCL-185 were
obtained at the 48 hr time-point. Legend: Blue horizontal line= p-value threshold of 0.01;
Red vertical dotted line= -4.0-fold change in expression and green vertical dotted line= +4.0fold change in expression, any gene expression data lying in between the two values was
evaluated as insignificant; Green transparent oval= indicative of data for CCL-185.

At the 100 µg/mL concentration of cotinine, both the normal, male cell line, and
the cancer cell line, showed no significant changes in expression for the seven candidate
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genes analyzed (Table 1). Oddly, the normal, female cell line, when exposed to the alkaloid
at the 100 µg/mL concentration, portrayed a decrease in expression, at the 48-hour timepoint, in AHR, ALDH3A1, CEACAM6, CYP1A1, GPX2, MDM2, and TP53. The most
prominent decrease in expression seen within the normal, female cell line was observed in
GPX2, where there was a decrease in fold change of -9.04 when normalized to the control.
Figure 25 features a volcano plot pertaining to this decrease in gene expression within the
normal, female cell line.
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Figure 25: Relative Normalized Gene Expression with Exposure to Cotinine at
100µg/mL.
Data obtained at 48 hours and 96 hours, on the three experimental cell lines, under the
exposure of cotinine at the 100 µg/mL concentration, was analyzed by qRT-PCR for
differential gene expression of seven candidate genes. Only cell lines displaying significant
differential expression of candidate genes are shown. All values obtained for CCL-186 were
obtained at the 48 hr time-point. Legend: Blue horizontal line= p-value threshold of 0.01;
Red vertical dotted line= -4.0-fold change in expression and green vertical dotted line= +4.0fold change in expression, any gene expression data lying in between the two values was
evaluated as insignificant; Red transparent oval= indicative of data for CCL-186.
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Nicotine
Perhaps the most surprising results found within the gene analysis studies were the
limited, significant differences in gene expression examined within the cells, upon
exposure to the well-known tobacco alkaloid, nicotine. Upon exposure to 10 µg/mL
nicotine, the normal, female cell line, and the cancer cell line, showed no significant
changes in expression in the seven candidate genes analyzed (Table 1), when normalized
to the control. The normal, male cell line, when exposed to the alkaloid at the 10 µg/mL
concentration, only showed an increase in expression in three candidate genes: ALDH3A1,
GPX2, and TP53, at the 48-hour time-point (Figure 26). Of these genes, the greatest
increase in expression was recorded in GPX2, where there was a 5.73-fold increase in
expression when normalized to the control. These significant findings within the normal,
male cell line, are featured in the volcano plot, Figure 26, below.
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Figure 26: Relative Normalized Gene Expression with Exposure to Nicotine at
10µg/mL.
Data obtained at 48 hours and 96 hours, on the three experimental cell lines, under the
exposure of nicotine at the 10 µg/mL concentration, was analyzed by qRT-PCR for
differential gene expression of seven candidate genes. Only cell lines displaying significant
differential expression of candidate genes are shown. All values obtained for CCL-171 were
obtained at the 48 hr time-point. Legend: Blue horizontal line= p-value threshold of 0.01;
Red vertical dotted line= -4.0-fold change in expression and green vertical dotted line= +4.0fold change in expression, any gene expression data lying in between the two values was
evaluated as insignificant; Blue transparent oval= indicative of data for CCL-171.
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At the highest exposure of nicotine, 100 µg/mL, findings were surprisingly similar to that
of cotinine at the highest concentration, where the normal, female cell line displayed a
primarily downregulatory response. In contrast, the normal, male also displayed
downregulation in at least one gene and continued a response of upregulation in another.
The normal, female cell line, when exposed to nicotine at the 100 µg/mL concentration,
showed a decrease in expression of AHR, ALDH3A1, CEACAM6, GPX2, MDM2, and
TP53, at the 48-hour time point. The greatest decrease was evaluated to be in ALDH3A1,
where there was a -6.69-fold change decrease, when normalized to the control.
The normal, male cell line, when exposed to nicotine at the 100 µg/mL
concentration, also showed a -5.08-fold-change decrease in expression for ALDH3A1,
when normalized to the control, at the 96-hour time-point. The male cell line also showed
a 4.06-fold-change increase, at the 48-hour time-point, for GPX2, when normalized to the
control. The volcano plot displayed in Figure 27, highlights these significant findings of
differential gene expression within the normal, female and normal, male cell lines.
Common genes that displayed a downregulatory response, between the two cell lines,
include ALDH3A1, where the -6.7- fold value is indicative of the normal, female lung cell
line, and the -5.1-fold value is indicative of the normal, male lung cell line.
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Differential Gene Expression When Exposed to Nicotine at
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Figure 27: Relative Normalized Gene Expression with Exposure to Nicotine at
100µg/mL.
Data obtained at 48 hours and 96 hours, on the three experimental cell lines, under the
exposure of nicotine at the 100 µg/mL concentration, was analyzed by qRT-PCR for
differential gene expression of seven candidate genes. Only cell lines displaying significant
differential expression of candidate genes are shown. All values obtained for CCL-171 were
obtained at the 48 and 96 hr time-points. Values shown for CCL-186 were obtained at the
48 hr time point. Legend: Blue horizontal line= p-value threshold of 0.01; Red vertical dotted
line= -4.0-fold change in expression and green vertical dotted line= +4.0-fold change in
expression, any gene expression data lying in between the two values was evaluated as
insignificant; Blue transparent oval= indicative of data for CCL-171. Red transparent
rectangle= indicative of data for CCL-186.

DISCUSSION
The aim of this study was to evaluate and analyze potential adverse effects of
electronic cigarette filling solutions on the growth and viability of human lung cells in
culture. This was to be carried out by investigating differences in cell proliferation and
gene expression among a panel of lung tissue cell lines that were exposed to the tobacco
alkaloids: anabasine, cotinine, myosmine, and nicotine, which have been recognized in
previous studies to be within e-cigarette filling solution (Trehy et al., 2011). We
hypothesized, based on prior research indicating tobacco alkaloids as contributing factors
to diseased states of the human body upon their exposure (Hecht & Hoffmann, 1988;
McBride et al., 1998; Wilp et al., 2002) that these four tobacco alkaloids would
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demonstrate an effect on the normal proliferation and viability of lung cells and modify
normal gene expression patterns in a manner that is both sex-specific and/or disease
specific. We further hypothesized that these changes in cellular growth and gene expression
patterns could offer insight to potential risk factors for lung disease associated with
exposure to e-cigarette compounds.

Effect of Alkaloid Exposure on Normal Cell Proliferation
Of the four alkaloids tested within this study, exposure to anabasine and myosmine
displayed the most notable significance in differential cellular proliferation and viability
within the panel of lung cell lines examined. Though brief, significant, increases in cellular
proliferation were observed after individual exposure to the two individual alkaloids,
anabasine and myosmine, ultimately, exposure to each alkaloid resulted in a pattern of
decreased cellular proliferation and viability within the lung cell lines. Myosmine, in
particular, presented the most significant results of this inhibition on cellular growth, where
surprisingly, exposure to this alkaloid at the highest concentration studied, resulted in a
complete loss of cellular viability within all three of the lung cell lines (Figure 19).
In contrast to the results seen with anabasine and myosmine, exposure to the wellknown tobacco alkaloid, nicotine, and its metabolite, cotinine, resulted in a more varied
response among the panel of lung cell lines, where few trends were able to be observed.
For example, both nicotine and cotinine were seen to individually demonstrate both
stimulatory and inhibitory effects on the normal, female cell line, and the cancer cell line,
and these effects differed not only between the different lung cell lines, but also between
different concentrations, and time-points. The only trend that was somewhat observed,
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however, was that of a slight, stimulatory effect seen on the normal, male cell line, by both
nicotine and cotinine, individually, and more of an inhibitory effect on the cancer cell line,
by cotinine.

Examination of Differential Gene Expression Patterns Associated with
Alkaloid Exposure
Seven candidate genes were investigated within this study to serve as biomarkers
for potential disease risks that may be associated with exposure to the tobacco alkaloids,
anabasine, cotinine, and nicotine, within the panel of lung cell lines studied. Table 1 within
this study outlines the potential biomarker function for each of the seven genes analyzed,
and the results of those that were differentially expressed are visualized in Table 8 below.

Table 8: Differential Expression of Candidate Genes by Lung Tissue Cell Lines
Gene

CCL-185

10 µg/mL Concentration
CCL-171 ♂

CCL-186 ♀

Anabasine C o t i n i n e N i c o t i n e Anabasine C o t i n i n e N i c o t i n e Anabasine C o t i n i n e N i c o t i n e

AHR
CEACAM6
CYP1A1
MDM2
TP53
ALDH3A1
GPX2

Gene

CCL-185

100 µg/mL Concentration
CCL-171 ♂

CCL-186 ♀

Anabasine C o t i n i n e N i c o t i n e Anabasine C o t i n i n e N i c o t i n e Anabasine C o t i n i n e N i c o t i n e

AHR
CEACAM6
CYP1A1
MDM2
TP53
ALDH3A1
GPX2

Red= indicative of downregulation; Green= indicative of upregulation; Grey= indicative of no differential expression
observed; All time points (48 hr and 96 hr) are included within the table.
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Of the tobacco alkaloids studied by exposure on the lung cell lines, anabasine
seemed to induce the most significant features of abnormal, differential gene expression,
by displaying upregulation in practically all seven candidate genes, chosen for their use as
biomarkers for cytotoxic damage and oxidative stress (GPX2, ALDH3A1, TP53), as well
as potential carcinogenesis (CYP1A1, CEACAM6, MDM2, TP53), among all three of the
lung cell lines, at varying concentrations and time-points within the study. This trend was
followed by cotinine, which also displayed significant upregulation in gene expression,
within all seven of the candidate genes, except for the tumor suppressor, TP53. This trend
was specifically observed, however, within the cancer cell line, at exposure to the lower
concentration of cotinine. Interestingly, as a contrast in response, significant
downregulation of the exact same candidate genes was also observed within the normal,
female cell line upon exposure to cotinine at the highest concentrations.
Unexpectedly, of all the alkaloids examined, nicotine was perhaps the least
influential on differential expression of the seven candidate genes studied. The only real
significance in upregulatory response was seen within three genes: ALDH3A1, GPX2, and
TP53, and only within the normal, male cell line at exposure to 10 µg/mL nicotine.
Interesting still, significant downregulation within the majority of the candidate genes, with
the exclusion of TP53, was once again seen in the normal, female cell line, at exposure to
the highest concentration of nicotine, which was similar to the effect observed within the
normal, female cell line from exposure to the highest concentration of cotinine.
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Potential Risk of Disease Pathology Associated with Alkaloid Exposure
Anabasine and Myosmine
Resultant cellular proliferation and viability observed within the lung cell lines
exposed to anabasine and myosmine, individually, displayed a downward trend in cell
growth and viability. This trend could be suggestive of an environment within the lung
tissue that is similar to diseased states such as COPD and other respiratory illnesses, where
an increased apoptotic cellular response is hallmark (Henson, Vandivier, & Douglas, 2006;
U.S. Department of Health and Human Services, 2010). The brief increase that was also
observed in cellular proliferation after exposure to the two individual alkaloids could also
be suggestive that anabasine/myosmine could possibly support a state of carcinogenesis
within lung tissue by suppressing apoptosis. Interestingly, this possibility is supported by
prior research indicating both anabasine and myosmine of reacting with nitrosating agents
to form carcinogenic compounds (Hecht & Hoffmann, 1988; Wilp et al., 2002), and also
by gene expression analysis studies carried out for anabasine exposure on the lung cell
lines.
Though myosmine was unable to be studied in gene expression analysis due to the
loss of cell viability when the lung cell lines were treated with higher concentrations of the
alkaloid, anabasine was able to be analyzed, and the resultant differential gene expression
data expectantly followed a similar trend as the resultant cell proliferation data obtained by
the cell lines exposed to anabasine. Upregulation that was seen in the xenobiotic
metabolizing protein producing genes: ALDH3A1, CYP1A1, and AHR, as well as cytotoxic
biomarkers such as GPX2, could possibly be suggestive of oxidative stress and cellular
damage within the cell (Patel et al., 2008; Yan & Chen, 2006). Also, the upregulation that
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was observed in at least one or all of the oncogenes and proto-oncogenes, CEACAM6,
CYP1A1, AHR, and MDM2, upon exposure at varying concentrations and time points, as
well as upregulation of the tumor suppressor gene, TP53, could also be possibly suggestive
of a state which is supportive of carcinogenesis within the cell (Blumenthal et al., 2007;
Chauhan et al., 2016; Hartl, 2012; Jones et al., 1998; McLemore et al., 1990; Nakachi et
al., 1993).

Nicotine and Cotinine
In contrast to anabasine and myosmine, exposure of the lung cell lines to nicotine,
and its metabolite, cotinine (individually), resulted in very diverse cell proliferation and
viability data, as well as gene expression analysis. The only real trend observed that could
be suggestive of an increased risk of disease, when taking both cellular proliferation and
gene expression analysis data into consideration, was the effect seen on the cancer cell line,
by exposure to cotinine. Upregulation of almost all seven candidate genes, upon exposure
to cotinine, was observed within the cell line, coupled with a significant downward trend
seen in cell proliferation and viability. These findings could be suggestive of non-cancerous
diseased states within lung tissue, which could be supported by the upregulation observed
in the cytotoxic and oxidative stress biomarkers, GPX2 and ALDH3A1 (Gebel et al., 2004;
Patel et al., 2008; Yan & Chen, 2006). The findings could also, however, be suggestive of
possibly the beginnings to a more carcinogenic state within the lung cells, which could be
supported by the observance of significant

upregulation

within the proto-

oncogenes/oncogenes, CYP1A1, CEACAM6, MDM2, and AHR (Blumenthal et al., 2005;
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Blumenthal et al., 2007; Chauhan et al., 2016; Jones et al., 1998; McLemore et al., 1990;
Nakachi et al., 1993).
In regards to nicotine, the normal, male cell line did display slightly differential cell
proliferation as well as differential expression of candidate genes, which could be
indications of disease risk, however, the results for the gene expression analysis studies
were still very close to control, and any upregulation that was displayed was only observed
in a few genes. These few genes the upregulation was observed in were biomarkers that
are mostly suggestive of slight cytotoxic damage and/or oxidative stress.

Differences Seen Across Gender and Disease Status Upon Alkaloid
Exposure
In regards to differences in cellular proliferation and expression of candidate genes,
across gender, when exposed to the four alkaloids observed within this study, the most
significant differences were seen within the normal, female cell line, when exposed to the
highest concentration of nicotine, and for the highest concentration of cotinine. When
exposed to either 100 µg/mL nicotine or 100 µg/mL cotinine, a downregulation in
expression of almost all candidate genes, excluding TP53, was observed within the normal,
female cell line. These findings could possibly be suggestive of a more cytotoxic response
of the cell line, in comparison to the normal, male cell line, upon exposure to higher
concentrations of nicotine and/or cotinine.
In regards to differences observed in cellular proliferation and expression of
candidate genes across disease status, when exposed to the four alkaloids, the most
significant differences were seen upon exposure of cotinine to the cancer cell line. At
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exposure to 10 µg/mL cotinine, the cancer cell line was observed to display upregulation
in all but one of the seven candidate genes analyzed. Neither the normal, male cell line, nor
the normal, female cell line displayed this upregulatory response in expression within the
candidate genes, upon exposure to the alkaloid, at any concentration.

CONCLUSION
In conclusion, the tobacco alkaloids, anabasine and myosmine found within ecigarette filling solution, have been shown within this study to cause abnormal gene
expression among lung tissue cells, within candidate genes serving as biomarkers for
tobacco-smoke induced diseases of the lung, as well as carcinogenesis of the lung, and/or
to cause differential cellular proliferation and viability among the lung tissue cell lines
studied. Surprisingly, the most well-known of the tobacco alkaloids, nicotine, as well its
lesser known metabolite, cotinine, were shown to have minimal effect on the lung tissue
cells. Of the two, only the alkaloid, cotinine, presented the possibility of an increased risk
of disease and carcinogenesis, but only among the already diseased, cancer cell line that
was utilized within this study.
In regards to differential cellular response to the alkaloids, presenting in a sexspecific manner, little support was seen within the cellular proliferation and viability results
that could firmly be attributed to differences due to gender alone, and differential
expression for the candidate genes, TP53 and CYP1A1, utilized for analyzation of any
gender differences, was also not observed within the study. However, the normal, female
cell line did, in comparison to the normal, male cell line, show a downregulation in most
of the analyzed candidate genes, upon exposure to the higher concentrations of nicotine
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and cotinine. The normal, female cell line also displayed an earlier response in differential
cellular proliferation and abnormal gene expression, from exposure to anabasine. These
results could possibly indicate an increased susceptibility in women to toxicity from
exposure to the three alkaloids, nicotine, cotinine, and anabasine, at lower concentrations
than what would cause the same effect in males. Further research supporting these
conclusions would be necessary, however, due to the limited findings.

LIMITATIONS/ FUTURE AIMS
In this pilot study examining the effects of tobacco alkaloid exposure on lung cell
proliferation, variable concentrations of each alkaloid were tested on a panel of lung cell
lines that differed with respect to gender and disease status. Moving forward, taking in
consideration the findings from this report, we recommend repeating the study with focus
on the 10 ug/mL exposure concentration, which was the dose that resulted in a measurable
effect on cell proliferation, but did not cause cell death. At this concentration, we can then
begin to address any synergistic or agonistic effects of exposure of the alkaloids in
combination. Ideally, however, the best exposure level would be one that is physiologically
relevant and reflects exposure encountered from normal e-cigarette inhalation. A major
limitation to the experimental design of this study is the mechanism and exposure route of
tobacco alkaloid administration in a liquid tissue culture system. Future studies should
investigate an exposure system that more readily mimics in vivo exposure to the e-cigarette
filling solution, once it becomes an aerosol that is inhaled by the e-cigarette user.
Another concern within this study was the growing pattern of the normal, female
lung tissue cell line, which seemed to be lower in its normal cellular proliferation growth
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curve than that of the other two lung tissue cell lines used within the study. The normal,
female lung tissue cell line was also the only lung tissue cell line used within this study,
that showed downregulation of candidate genes. In order to ensure that the observation of
differences seen between the normal, female lung tissue cell line and that of the male, was
due to gender differences alone, the incorporation of another normal, female cell line
should be used, in order to support or oppose results seen within this study concerning the
results obtained for the normal, female cell line, CCL-186.
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Appendix 1: Two-Tailed Student T-Test Results
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Appendix 2: Cell Growth with Exposure to 1 µg/mL Anabasine, Normalized to Control.

Anabasine Exposure at 1 µg/mL
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Data obtained daily on the three experimental cell lines, under the exposure of anabasine at the 1 µg/mL
concentration, by the CellTiter-Glo® luminescent viability assay, was normalized to the control by applying an
equation of percent difference for each time-point within the 10-day time course. The legend indicates the
associated colors for the three varying cell lines: normal male = CCL-171, normal female = CCL-186, and
cancerous male = CCL-185.
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Appendix 3: Cell Growth with Exposure to 1 µg/mL Cotinine, Normalized to Control

Cotinine Exposure at 1 µg/mL
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Incubation Time-point (days)
Data obtained daily on the three experimental cell lines, under the exposure of cotinine at the 1 µg/mL
concentration, by the CellTiter-Glo® luminescent viability assay, was normalized to the control by applying an
equation of percent difference for each time-point within the 10-day time course. The legend indicates the
associated colors for the three varying cell lines: normal male = CCL-171, normal female = CCL-186, and
cancerous male = CCL-185.
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Appendix 4: Cell Growth with Exposure to 1 µg/mL Myosmine, Normalized to Control

Myosmine Exposure at 1 µg/mL
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Incubation Time-point (days)
Data obtained daily on the three experimental cell lines, under the exposure of myosmine at the 1 µg/mL
concentration, by the CellTiter-Glo® luminescent viability assay, was normalized to the control by applying an
equation of percent difference for each time-point within the 10-day time course. The legend indicates the
associated colors for the three varying cell lines: normal male = CCL-171, normal female = CCL-186, and
cancerous male = CCL-185.
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Appendix 5: Cell Growth with Exposure to 1 µg/mL Nicotine, Normalized to Control

Nicotine Exposure at 1 µg/mL
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Data obtained daily on the three experimental cell lines, under the exposure of nicotine at the 1 µg/mL
concentration, by the CellTiter-Glo® luminescent viability assay, was normalized to the control by applying an
equation of percent difference for each time-point within the 10-day time course. The legend indicates the
associated colors for the three varying cell lines: normal male = CCL-171, normal female = CCL-186, and
cancerous male = CCL-185.
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